19. Referanser

Aapro, M. S., Bohlius, J., Cameron, D. A., Dal Lago, L., Donnelly, J. P., Kearney, N., Lyman, G. H., Pettengell, R., ... Treatment of, C. (2011). 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. European journal of cancer, 47(1), 8-32.

Aas, T., Geisler, S., Paulsen, T., Borresen-Dale, A. L., Varhaug, J. E., Lonning, P. E., & Akslen, L. A. (1996). Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Acta Oncologica, 35(Suppl 5), 5-8.

Abeloos, C. H., Purswani, J. M., Galavis, P., McCarthy, A., Hitchen, C., Choi, J. I., & Gerber, N. K. (2023). Different Re-Irradiation Techniques after Breast-Conserving Surgery for Recurrent or New Primary Breast Cancer. Current oncology, 30(1), 1151-1163.

Aberizk, W. J., Silver, B., Henderson, I. C., Cady, B., & Harris, J. R. (1986). The use of radiotherapy for treatment of isolated locoregional recurrence of breast carcinoma after mastectomy. Cancer, 58(6), 1214-1218.

Abner, A. L., Recht, A., Eberlein, T., Come, S., Shulman, L., Hayes, D., Connolly, J. L., Schnitt, S. J., ... Harris, J. R. (1993). Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. Journal of clinical oncology, 11(1), 44-8.

ACOG (2014). Tamoxifen and Uterine Cancer (Number 601, June 2014). Washington, DC: The American College of Obstetricians and Gynecologists, Committee on Gynecologic Practice. Hentet fra https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2014/06/tamoxifen-and-uterine-cancer

Aebi, S., Gelber, S., Anderson, S. J., Láng, I., Robidoux, A., Martin, M., Nortier, J. W., Paterson, A. H., ... Wapnir, I. L. (2014). Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. The Lancet. Oncology, 15(2), 156-63.

Agresti, R., Martelli, G., Sandri, M., Tagliabue, E., Carcangiu, M. L., Maugeri, I., Pellitteri, C., Ferraris, C., ... Pierotti, M. A. (2014). Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: a randomized clinical trial (INT09/98). Cancer, 120(6), 885-93.

Albain, K. S., Barlow, W. E., Shak, S., Hortobagyi, G. N., Livingston, R. B., Yeh, I. T., Ravdin, P., Bugarini, R., ... Hayes, D. F. (2010). Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. The Lancet. Oncology, 11(1), 55-65.

Alkis, N., Durnali, A. G., Arslan, U. Y., Kocer, M., Onder, F. O., Tokluoglu, S., Celenkoglu, G., Muallaoglu, S., ... Altundag, K. (2011). Optimal timing of adjuvant treatment in patients with early breast cancer. Medical oncology, 28(4), 1255-1259.

Allred, D. C., Anderson, S. J., Paik, S., Wickerham, D. L., Nagtegaal, I. D., Swain, S. M., Mamounas, E. P., Julian, T. B., ... Wolmark, N. (2012). Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. Journal of clinical oncology, 30(12), 1268-73.

Alpert, T. E., Kuerer, H. M., Arthur, D. W., Lannin, D. R., & Haffty, B. G. (2005). Ipsilateral breast tumor recurrence after breast conservation therapy: outcomes of salvage mastectomy vs. salvage breast-conserving surgery and prognostic factors for salvage breast preservation. International journal of radiation oncology, biology, physics, 63(3), 845-51.

Alterio, D., Jereczek-Fossa, B. A., Franchi, B., D'Onofrio, A., Piazzi, V., Rondi, E., Ciocca, M., Gibelli, B., ... Orecchia, R. (2007). Thyroid disorders in patients treated with radiotherapy for head-and-neck cancer: a retrospective analysis of seventy-three patients. International journal of radiation oncology, biology, physics, 67(1), 144-150.

Amant, F., Loibl, S., Neven, P., & Van Calsteren, K. (2012). Breast cancer in pregnancy. Lancet, 379(9815), 570-9.

Amant, F., von Minckwitz, G., Han, S. N., Bontenbal, M., Ring, A. E., Giermek, J., Wildiers, H., Fehm, T., ... Loibl, S. (2013). Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. Journal of clinical oncology, 31(20), 2532-9.

Amant, F., Han, S. N., Gziri, M. M., Vandenbroucke, T., Verheecke, M., & Van Calsteren, K. (2015). Management of cancer in pregnancy. Best practice & research. Clinical obstetrics & gynaecology, 29(5), 741-53.

Amant, F., Vandenbroucke, T., Verheecke, M., Fumagalli, M., Halaska, M. J., Boere, I., Han, S., Gziri, M. M., ... Van Calsteren, K. (2015). Pediatric Outcome after Maternal Cancer Diagnosed during Pregnancy. New England Journal of Medicine, 373(19), 1824-34.

The American Society of Breast surgeons (2018). Consensus Guideline on Concordance Assessment of Image-Guided Breast Biopsies and Management of Borderline or High-Risk Lesions Columbia, MD: The American Society of Breast surgeons. Hentet fra https://www.breastsurgeons.org/docs/statements/Consensus-Guideline-on-Concordance-Assessment-of-Image-Guided-Breast-Biopsies.pdf

American College of Radiology (2007). Practice guideline for the breast conservation therapy in the management of invasive breast carcinoma. Journal of the American College of Surgeons, 205(2), 362-376.

Amir, E., Seruga, B., Niraula, S., Carlsson, L., & Ocana, A. (2011). Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. Journal of the National Cancer Institute, 103(17), 1299-1309.

An, X., Lei, X., Huang, R., Luo, R., Li, H., Xu, F., Yuan, Z., Wang, S., ... Shi, Y. (2020). Adjuvant chemotherapy for small, lymph node-negative, triple-negative breast cancer: A single-center study and a meta-analysis of the published literature. Cancer, 126 Suppl 16, 3837-3846.

Anbazhagan, R., Fujii, H., & Gabrielson, E. (1999). Microsatellite instability is uncommon in breast cancer. Clinical cancer research, 5(4), 839-44.

Anderson, S. J., Wapnir, I., Dignam, J. J., Fisher, B., Mamounas, E. P., Jeong, J. H., Geyer, C. E. ,., Wickerham, D. L., ... Wolmark, N. (2009). Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. Journal of clinical oncology, 27(15), 2466-2473.

Andersson, M., Lidbrink, E., Bjerre, K., Wist, E., Enevoldsen, K., Jensen, A. B., Karlsson, P., Tange, U. B., ... Langkjer, S. T. (2011). Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. Journal of clinical oncology, 29(3), 264-271.

Andre, F., Ismaila, N., Henry, N. L., Somerfield, M. R., Bast, R. C., Barlow, W., Collyar, D. E., Hammond, M. E., ... Stearns, V. (2019). Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update-Integration of Results From TAILORx. Journal of clinical oncology, 37(22), 1956-1964.

Andre, F., Broglio, K., Roche, H., Martin, M., Mackey, J. R., Penault-Llorca, F., Hortobagyi, G. N., & Pusztai, L. (2008). Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis. Journal of clinical oncology, 26(16), 2636-2643.

Andre, F., Ismaila, N., Allison, K. H., Barlow, W. E., Collyar, D. E., Damodaran, S., Henry, N. L., Jhaveri, K., ... Stearns, V. (2022). Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. Journal of clinical oncology, 40(16), 1816-1837.

Andre, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., ... Group, S. S. (2019). Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. New England Journal of Medicine, 380(20), 1929-1940.

André, F., Hee Park, Y., Kim, S. B., Takano, T., Im, S. A., Borges, G., Lima, J. P., Aksoy, S., ... Krop, I. (2023). Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet, 401(10390), 1773-1785.

André, F., Ciruelos, E. M., Juric, D., Loibl, S., Campone, M., Mayer, I. A., Rubovszky, G., Yamashita, T., ... Rugo, H. S. (2021). Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. Annals of oncology, 32(2), 208-217.

Appelt, A. L., Vogelius, I. R., & Bentzen, S. M. (2013). Modern hypofractionation schedules for tangential whole breast irradiation decrease the fraction size-corrected dose to the heart. Clinical oncology (Royal College of Radiologists (Great Britain)), 25(3), 147-152.

Arecco, L., Blondeaux, E., Bruzzone, M., Ceppi, M., Latocca, M. M., Marrocco, C., Boutros, A., Spagnolo, F., ... Lambertini, M. (2022). Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis. Human reproduction, 37(5), 954-968.

Arthur, D. W., Winter, K. A., Kuerer, H. M., Haffty, B., Cuttino, L., Todor, D. A., Anne, P. R., Anderson, P., ... White, J. R. (2020). Effectiveness of Breast-Conserving Surgery and 3-Dimensional Conformal Partial Breast Reirradiation for Recurrence of Breast Cancer in the Ipsilateral Breast: The NRG Oncology/RTOG 1014 Phase 2 Clinical Trial. JAMA oncology, 6(1), 75-82.

Ashkanani, F., Sarkar, T., Needham, G., Coldwells, A., Ah-See, A. K., Gilbert, F. J., Hutcheon, A. W., Eremin, O., & Heys, S. D. (2001). What is achieved by mammographic surveillance after breast conservation treatment for breast cancer?. American journal of surgery, 182(3), 207-10.

Asleh, K., Lluch, A., Goytain, A., Barrios, C., Wang, X. Q., Torrecillas, L., Gao, D., Ruiz-Borrego, M., ... Martin, M. (2023). Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine. Clinical cancer research, 29(2), 389-400.

Aubert, R. E., Stanek, E. J., Yao, J., Teagarden, J. R., Subar, M., Epstein, R. S., Skaar, T. C., Desta, Z., & Flockhart, D. A. (2009). Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. Journal of clinical oncology, 27(18 suppl), abstract CRA508.

Avila, A., Bartholomew, A. J., Sosin, M., Deldar, R., Griffith, K. F., Willey, S. C., Song, D. H., Fan, K. L., & Tousimis, E. A. (2020). Acute Postoperative Complications in Prepectoral versus Subpectoral Reconstruction following Nipple-Sparing Mastectomy. Plastic and reconstructive surgery, 146(6), 715e-720e.

Azim, H. A. ,. J., Santoro, L., Russell-Edu, W., Pentheroudakis, G., Pavlidis, N., & Peccatori, F. A. (2012). Prognosis of pregnancy-associated breast cancer: a meta-analysis of 30 studies. Cancer Treatment Reviews, 38(7), 834-42.

Azim, A. A., Costantini-Ferrando, M., & Oktay, K. (2012). Safety of Fertility Preservation by Ovarian Stimulation With Letrozole and Gonadotropins in Patients With Breast Cancer: A Prospective Controlled Study. Journal of clinical oncology, 26(16), 2630-2635.

Aziz, S., Wik, E., Knutsvik, G., Klingen, T. A., Chen, Y., Davidsen, B., Aas, H., Aas, T., & Akslen, L. A. (2017). Extra-nodal extension is a significant prognostic factor in lymph node positive breast cancer. PLoS ONE, 12(2), e0171853.

Baak, J. P., van Diest, P. J., Janssen, E. A., Gudlaugsson, E., Voorhorst, F. J., van der Wall, E., & Vermorken, J. B. (2008). Proliferation accurately identifies the high-risk patients among small, low-grade, lymph node-negative invasive breast cancers. Annals of oncology, 19(4), 649-54.

Baak, J. P., van Diest, P. J., Voorhorst, F. J., van der Wall, E., Beex, L. V., Vermorken, J. B., Janssen, E. A., & Gudlaugsson, E. (2007). The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent. European journal of cancer, 43(3), 527-35.

Bachelot, T., Bourgier, C., Cropet, C., Ray-Coquard, I., Ferrero, J. M., Freyer, G., Abadie-Lacourtoisie, S., Eymard, J. C., ... Pujade-Lauraine, E. (2012). Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. Journal of clinical oncology, 30(22), 2718-2724.

Baek, S. Y., Noh, W. C., Ahn, S. H., Kim, H. A., Ryu, J. M., Kim, S. I., Lee, E. G., Im, S. A., ... Kim, H. J. (2023). Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial. Journal of clinical oncology, 41(31), 4864-4871.

Bailey, A. G., Brown, J. N., & Hammond, J. M. (2021). Cryotherapy for the prevention of chemotherapy-induced peripheral neuropathy: A systematic review. Journal of oncology pharmacy practice, 27(1), 156-164.

Baker, N. F., Baecher, K. M., Hart, A. M., Styblo, T. M., Carlson, G. W., & Losken, A. (2020). The impact of axillary node surgery on outcomes following immediate breast reconstruction. The breast journal, 26(11), 2170-2176.

Baltzer, P., Mann, R. M., Iima, M., Sigmund, E. E., Clauser, P., Gilbert, F. J., Martincich, L., Partridge, S. C., ... Le Bihan, D. (2020). Diffusion-weighted imaging of the breast-a consensus and mission statement from the EUSOBI International Breast Diffusion-Weighted Imaging working group. European radiology, 30(3), 1436-1450.

Banke, A., Fosbøl, E. L., Møller, J. E., Gislason, G. H., Andersen, M., Bernsdorf, M., Jensen, M. B., Schou, M., & Ejlertsen, B. (2018). Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: insight from a randomized clinical trial. European journal of heart failure, 20(10), 1447-1453.

Banuelos, J., Sabbagh, M. D., Roh, S. G., Nguyen, M. T., Lemaine, V., Tran, N. V., Jacobson, S. R., Boughey, J. C., ... Sharaf, B. (2019). Infections following Immediate Implant-Based Breast Reconstruction: A Case-Control Study over 11 Years. Plastic and reconstructive surgery, 144(6), 1270-1277.

Bardia, A., Cortés, J., Bidard, F. C., Neven, P., Garcia-Sáenz, J., Aftimos, P., O'Shaughnessy, J., Lu, J., ... Kaklamani, V. (2024). Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups. Clinical cancer research, 30(19), 4299-4309.

Bardia, A., Hu, X., Dent, R., Yonemori, K., Barrios, C. H., O'Shaughnessy, J. A., Wildiers, H., Pierga, J. Y., ... Curigliano, G. (2024). Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer. New England Journal of Medicine, 391(22), 2110-2122.

Bardia, A., Rugo, H. S., Tolaney, S. M., Loirat, D., Punie, K., Oliveira, M., Brufsky, A., Kalinsky, K., ... Hurvitz, S. A. (2024). Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression. Journal of clinical oncology, 42(15), 1738-1744.

Bartelink, H., Maingon, P., Poortmans, P., Weltens, C., Fourquet, A., Jager, J., Schinagl, D., Oei, B., ... Collette, L. (2015). Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. The Lancet. Oncology, 16(1), 47-56.

Bartelink, H., Horiot, J. C., Poortmans, P. M., Struikmans, H., Van den Bogaert, W., Fourquet, A., Jager, J. J., Hoogenraad, W. J., ... Collette, L. (2007). Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. Journal of clinical oncology, 25(22), 3259-3265.

Bartelink, H., Horiot, J. C., Poortmans, P., Struikmans, H., Van den Bogaert, W., Barillot, I., Fourquet, A., Borger, J., ... Pierart, M. (2001). Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. New England Journal of Medicine, 345(19), 1378-1387.

Bartels, S. A. L., Donker, M., Poncet, C., Sauvé, N., Straver, M. E., van de Velde, C. J. H., Mansel, R. E., Blanken, C., ... Rutgers, E. J. T. (2023). Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial. Journal of clinical oncology, 41(12), 2159-2165.

Baselga, J. (2011). Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist, 16 Suppl 1, 12-9.

Baselga, J., Im, S. A., Iwata, H., Cortes, J., De Laurentiis, M., Jiang, Z., Arteaga, C. L., Jonat, W., ... Campone, M. (2017). Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, 18(7), 904-916.

Baselga, J., Campone, M., Piccart, M., Burris, H. A. ,. 3., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., ... Hortobagyi, G. N. (2012). Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. New England Journal of Medicine, 366(6), 520-529.

Baselga, J., Cortes, J., Kim, S. B., Im, S. A., Hegg, R., Im, Y. H., Roman, L., Pedrini, J. L., ... Swain, S. M. (2012). Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. New England Journal of Medicine, 366(2), 109-119.

Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J., Guthrie, T., Shah, P., Khojasteh, A., ... Lee, L. W. (2001). Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. Journal of clinical oncology, 19(5), 1444-54.

Beck, T. M., Hart, N. E., Woodard, D. A., & Smith, C. E. (1983). Local or regionally recurrent carcinoma of the breast: results of therapy in 121 patients. Journal of clinical oncology, 1(6), 400-405.

Bellini, C., Nori Cucchiari, J., Di Naro, F., De Benedetto, D., Bicchierai, G., Franconeri, A., Renda, I., Bianchi, S., & Susini, T. (2023). Breast Lesions of Uncertain Malignant Potential (B3) and the Risk of Breast Cancer Development: A Long-Term Follow-Up Study. Cancers (Basel), 15(13)

Bentzen, S. M., Agrawal, R. K., Aird, E. G., Barrett, J. M., Barrett-Lee, P. J., Bentzen, S. M., Bliss, J. M., Brown, J., ... Yarnold, J. R. (2008). The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet, 371(9618), 1098-1107.

Beral, V. (2003). Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet, 362(9382), 419-427.

Beresford, M., Tumur, I., Chakrabarti, J., Barden, J., Rao, N., & Makris, A. (2011). A qualitative systematic review of the evidence base for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic breast cancer. Clinical oncology (Royal College of Radiologists (Great Britain)), 23(3), 209-215.

Bernstein, J. L., Teraoka, S., Southey, M. C., Jenkins, M. A., Andrulis, I. L., Knight, J. A., John, E. M., Lapinski, R., ... Concannon, P. (2006). Population-based estimates of breast cancer risks associated with ATM gene variants c.7271T>G and c.1066-6T>G (IVS10-6T>G) from the Breast Cancer Family Registry. Human mutation, 27(11), 1122-8.

Berrington de Gonzalez, A., Berg, C. D., Visvanathan, K., & Robson, M. (2009). Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers. Journal of the National Cancer Institute, 101(3), 205-9.

Berry, D. A., Cirrincione, C., Henderson, I. C., Citron, M. L., Budman, D. R., Goldstein, L. J., Martino, S., Perez, E. A., ... Winer, E. P. (2006). Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA, 295(14), 1658-1667.

Bidard, F. C., Kaklamani, V. G., Neven, P., Streich, G., Montero, A. J., Forget, F., Mouret-Reynier, M. A., Sohn, J. H., ... Bardia, A. (2022). Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. Journal of clinical oncology, 40(28), 3246-3256.

Biganzoli, L., Battisti, N. M. L., Wildiers, H., McCartney, A., Colloca, G., Kunkler, I. H., Cardoso, M. J., Cheung, K. L., ... Brain, E. G. C. (2021). Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG). The Lancet. Oncology, 22(7), e327-e340.

Biganzoli, L., Wildiers, H., Oakman, C., Marotti, L., Loibl, S., Kunkler, I., Reed, M., Ciatto, S., ... Audisio, R. (2012). Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). The Lancet. Oncology, 13(4), e148-e160.

Bijker, N., Donker, M., Wesseling, J., den Heeten, G. J., & Rutgers, E. J. (2013). Is DCIS breast cancer, and how do I treat it?. Current treatment options in oncology, 14(1), 75-87.

Bijker, N., Meijnen, P., Peterse, J. L., Bogaerts, J., Van Hoorebeeck, I., Julien, J. P., Gennaro, M., Rouanet, P., ... Rutgers, E. J. (2006). Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Journal of clinical oncology, 24(21), 3381-3387.

Bijker, N., Peterse, J. L., Duchateau, L., Julien, J. P., Fentiman, I. S., Duval, C., Di Palma, S., Simony-Lafontaine, J., ... van de Vijver, M. J. (2001). Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. Journal of clinical oncology, 19(8), 2263-2271.

Bines, J., Oleske, D. M., & Cobleigh, M. A. (1996). Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. Journal of clinical oncology, 14(5), 1718-29.

Blair, V. R., McLeod, M., Carneiro, F., Coit, D. G., D'Addario, J. L., van Dieren, J. M., Harris, K. L., Hoogerbrugge, N., ... Guilford, P. (2020). Hereditary diffuse gastric cancer: updated clinical practice guidelines. The Lancet. Oncology, 21(8), e386-e397.

Bliss, J. M., Kilburn, L. S., Coleman, R. E., Forbes, J. F., Coates, A. S., Jones, S. E., Jassem, J., Delozier, T., ... Coombes, R. C. (2012). Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. Journal of clinical oncology, 30(7), 709-717.

Blohmer, J. U., Link, T., Reinisch, M., Just, M., Untch, M., Stötzer, O., Fasching, P. A., Schneeweiss, A., ... Loibl, S. (2022). Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial. JAMA oncology, 8(7), 1010-1018.

Blok, E. J., Kroep, J. R., Meershoek-Klein Kranenbarg, E., Duijm-de Carpentier, M., Putter, H., van den Bosch, J., Maartense, E., van Leeuwen-Stok, A. E., ... van de Velde, C. J. H. (2018). Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05). Journal of the National Cancer Institute, 110(1)

Blough, J. T., Vu, M. M., Qiu, C. S., Mlodinow, A. S., Khavanin, N., Fine, N. A., & Kim, J. Y. S. (2018). Beyond 30 Days: A Risk Calculator for Longer Term Outcomes of Prosthetic Breast Reconstruction. Plastic and reconstructive surgery. Global open, 6(12), e2065.

Blum, J. L., Dieras, V., Lo Russo, P. M., Horton, J., Rutman, O., Buzdar, A., & Osterwalder, B. (2001). Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer, 92(7), 1759-1768.

Blum, J. L., Flynn, P. J., Yothers, G., Asmar, L., Geyer, C. E. ,. J., Jacobs, S. A., Robert, N. J., Hopkins, J. O., ... Wolmark, N. (2017). Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). Journal of clinical oncology, 35(23), 2647-2655.

Blumgart, E. I., Uren, R. F., Nielsen, P. M., Nash, M. P., & Reynolds, H. M. (2011). Predicting lymphatic drainage patterns and primary tumour location in patients with breast cancer. Breast cancer research and treatment, 130(2), 699-705.

Body, J. J., Diel, I. J., Lichinitser, M. R., Kreuser, E. D., Dornoff, W., Gorbunova, V. A., Budde, M., & Bergstrom, B. (2003). Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Annals of oncology, 14(9), 1399-1405.

Body, J. J., Diel, I. J., Lichinitzer, M., Lazarev, A., Pecherstorfer, M., Bell, R., Tripathy, D., & Bergstrom, B. (2004). Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. British Journal of Cancer, 90(6), 1133-1137.

Bonneterre, J., Roche, H., Kerbrat, P., Bremond, A., Fumoleau, P., Namer, M., Goudier, M. J., Schraub, S., ... Chapelle-Marcillac, I. (2005). Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. Journal of clinical oncology, 23(12), 2686-2693.

Bookman, M. A., & Longo, D. L. (1986). Concomitant illness in patients treated for Hodgkin's disease. Cancer Treatment Reviews, 13(2), 77-111.

Borner, M., Bacchi, M., Goldhirsch, A., Greiner, R., Harder, F., Castiglione, M., Jungi, W. F., Thurlimann, B., ... Obrecht, J. P. (1994). First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research. Journal of clinical oncology, 12(10), 2071-2077.

Borud, E. K., Alraek, T., & White, A. (2010). The Acupuncture on Hot Flashes Among Menopausal Women study: observational follow-up results at 6 and 12 months. Menopause, 17(2), 262-268.

Bose, R., Kavuri, S. M., Searleman, A. C., Shen, W., Shen, D., Koboldt, D. C., Monsey, J., Goel, N., ... Ellis, M. J. (2013). Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discovery, 3(2), 224-37.

Bouchardy, C., Rapiti, E., Blagojevic, S., Vlastos, A. T., & Vlastos, G. (2007). Older female cancer patients: importance, causes, and consequences of undertreatment. Journal of clinical oncology, 25(14), 1858-1869.

Brackstone, M., Baldassarre, F. G., Perera, F. E., Cil, T., Chavez Mac Gregor, M., Dayes, I. S., Engel, J., Horton, J. K., ... Eisen, A. F. (2021). Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline. Journal of clinical oncology, 39(27), 3056-3082.

Breast Cancer Association, C., Mavaddat, N., Dorling, L., Carvalho, S., Allen, J., Gonzalez-Neira, A., Keeman, R., Bolla, M. K., ... Easton, D. F. (2022). Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes. JAMA oncology, 8(3), e216744.

Breast Cancer Association Consortium, Dorling, L., Carvalho, S., Allen, J., González-Neira, A., Luccarini, C., Wahlström, C., Pooley, K. A., ... Easton, D. F. (2021). Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. New England Journal of Medicine, 384(5), 428-439.

Brierley, J. D., Gospodarowicz, M. K., Wittekind, C. (2017). TNM: classification of malignant tumours. John Wiley & Sons.

Brinton, L. A., Key, T. J., Kolonel, L. N., Michels, K. B., Sesso, H. D., Ursin, G., Van Den Eeden, S. K., Wood, S. N., ... Cook, M. B. (2015). Prediagnostic Sex Steroid Hormones in Relation to Male Breast Cancer Risk. Journal of clinical oncology, 33(18), 2041-50.

Brodowicz, T., Kostler, W. J., Moslinger, R., Tomek, S., Vaclavik, I., Herscovici, V., Wiltschke, C., Steger, G. G., ... Zielinski, C. C. (2000). Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer. Breast, 9(6), 338-342.

Broeders, M., Moss, S., Nystrom, L., Njor, S., Jonsson, H., Paap, E., Massat, N., Duffy, S., ... Paci, E. (2012). The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. Journal of medical screening, 19 Suppl 1, 14-25.

Broglio, K. R., Quintana, M., Foster, M., Olinger, M., McGlothlin, A., Berry, S. M., Boileau, J. F., Brezden-Masley, C., ... Berry, D. A. (2016). Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis. JAMA oncology, 2(6), 751-60.

Browall, M., Forsberg, C., & Wengström, Y. (2017). Assessing patient outcomes and cost-effectiveness of nurse-led follow-up for women with breast cancer - have relevant and sensitive evaluation measures been used?. Journal of clinical nursing, 26(13-14), 1770-1786.

Brown, T., Cruickshank, S., & Noblet, M. (2021). Specialist breast care nurses for support of women with breast cancer. Cochrane database of systematic reviews, 2(2), CD005634.

Brufsky, A. M., Harker, W. G., Beck, J. T., Bosserman, L., Vogel, C., Seidler, C., Jin, L., Warsi, G., ... Perez, E. A. (2012). Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole. Cancer, 118(5), 1192-1201.

Brunt, A. M., Wheatley, D., Yarnold, J., Somaiah, N., Kelly, S., Harnett, A., Coles, C., Goodman, A., ... Bliss, J. M. (2016). Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiotherapy and Oncology, 120(1), 114-8.

Buchanan, C. L., Dorn, P. L., Fey, J., Giron, G., Naik, A., Mendez, J., Murphy, C., & Sclafani, L. M. (2006). Locoregional recurrence after mastectomy: incidence and outcomes. Journal of the American College of Surgeons, 203(4), 469-474.

Buchholz, T. A., Tucker, S. L., Masullo, L., Kuerer, H. M., Erwin, J., Salas, J., Frye, D., Strom, E. A., ... Hortobagyi, G. N. (2002). Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. Journal of clinical oncology, 20(1), 17-23.

Burstein, H. J., Curigliano, G., Loibl, S., Dubsky, P., Gnant, M., Poortmans, P., Colleoni, M., Denkert, C., ... Thurlimann, B. (2019). Estimating the Benefits of Therapy for Early Stage Breast Cancer The St Gallen International Consensus Guidelines for the Primary Therapy of Early Breast Cancer 2019. Annals of oncology, 30(10), 1541-1557.

Burstein, H. J., Curigliano, G., Thürlimann, B., Weber, W. P., Poortmans, P., Regan, M. M., Senn, H. J., Winer, E. P., & Gnant, M. (2021). Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Annals of oncology, 32(10), 1216-1235.

Burstein, H. J., Somerfield, M. R., Barton, D. L., Dorris, A., Fallowfield, L. J., Jain, D., Johnston, S. R. D., Korde, L. A., ... Rugo, H. S. (2021). Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. Journal of clinical oncology, 39(35), 3959-3977.

Burstein, H. J., DeMichele, A., Fallowfield, L., Somerfield, M. R., & Henry, N. L. (2024). Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update. Journal of clinical oncology, 42(12), 1450-1453.

Butt, D. A., Lock, M., Lewis, J. E., Ross, S., & Moineddin, R. (2008). Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial. Menopause, 15(2), 310-318.

Byrski, T., Huzarski, T., Dent, R., Marczyk, E., Jasiowka, M., Gronwald, J., Jakubowicz, J., Cybulski, C., ... Narod, S. A. (2014). Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast cancer research and treatment, 147(2), 401-5.

Cabioglu, N., Hunt, K. K., Buchholz, T. A., Mirza, N., Singletary, S. E., Kuerer, H. M., Babiera, G. V., Ames, F. C., ... Meric-Bernstam, F. (2005). Improving local control with breast-conserving therapy: a 27-year single-institution experience. Cancer, 104(1), 20-29.

Cameron, D., Piccart-Gebhart, M. J., Gelber, R. D., Procter, M., Goldhirsch, A., de Azambuja, E., Castro, G. ,. J., Untch, M., ... Jackisch, C. (2017). 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet, 389(10075), 1195-1205.

Campbell, E. J., & Romics, L. (2017). Oncological safety and cosmetic outcomes in oncoplastic breast conservation surgery, a review of the best level of evidence literature. Breast Cancer: Targets and Therapy, 9, 521-530.

Caplin, D. A., Calobrace, M. B., Wixtrom, R. N., Estes, M. M., & Canady, J. W. (2021). MemoryGel Breast Implants: Final Safety and Efficacy Results after 10 Years of Follow-Up. Plastic and reconstructive surgery, 147(3), 556-566.

Carbine, N. E., Lostumbo, L., Wallace, J., & Ko, H. (2018). Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane database of systematic reviews, 4(4), CD002748.

Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019). Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Annals of oncology, 30(8), 1194-1220.

Cardoso, F., van't Veer, L. J., Bogaerts, J., Slaets, L., Viale, G., Delaloge, S., Pierga, J. Y., Brain, E., ... Piccart, M. (2016). 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. New England Journal of Medicine, 375(8), 717-29.

Cardoso, F., Paluch-Shimon, S., Schumacher-Wulf, E., Matos, L., Gelmon, K., Aapro, M. S., Bajpai, J., Barrios, C. H., ... Winer, E. P. (2024). 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast, 76, 103756.

Cardoso, F., Paluch-Shimon, S., Senkus, E., Curigliano, G., Aapro, M. S., André, F., Barrios, C. H., Bergh, J., ... Winer, E. P. (2020). 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Annals of oncology, 31(12), 1623-1649.

Carrick, S., Parker, S., Wilcken, N., Ghersi, D., Marzo, M., & Simes, J. (2009). Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane database of systematic reviews, (2), CD003372.

Carton, C., Evans, D. G., Blanco, I., Friedrich, R. E., Ferner, R. E., Farschtschi, S., Salvador, H., Azizi, A. A., ... Group, E. G. N. T. M. G. (2023). ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1. EClinicalMedicine, 56, 101818.

Casella, D., Di Taranto, G., Onesti, M. G., Greco, M., & Ribuffo, D. (2019). A retrospective comparative analysis of risk factors and outcomes in direct-to-implant and two-stages prepectoral breast reconstruction: BMI and radiotherapy as new selection criteria of patients. European journal of surgical oncology, 45(8), 1357-1363.

Casella, D., Di Taranto, G., Marcasciano, M., Lo Torto, F., Barellini, L., Sordi, S., Gaggelli, I., Roncella, M., ... Ribuffo, D. (2019). Subcutaneous expanders and synthetic mesh for breast reconstruction: Long-term and patient-reported BREAST-Q outcomes of a single-center prospective study. Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 72(5), 805-812.

Caudle, K. E., Sangkuhl, K., Whirl-Carrillo, M., Swen, J. J., Haidar, C. E., Klein, T. E., Gammal, R. S., Relling, M. V., ... Gaedigk, A. (2020). Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clinical and translational science, 13(1), 116-124.

Chan, S., Davidson, N., Juozaityte, E., Erdkamp, F., Pluzanska, A., Azarnia, N., & Lee, L. W. (2004). Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Annals of oncology, 15(10), 1527-34.

Chan, A., Martin, M., Untch, M., Gil, M. G., Guillem-Porta, V., Wojtukiewicz, M., Kellokumpu-Lehtinen, P., Sommer, H. L., ... Petruzelka, L. (2006). Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. British Journal of Cancer, 95(7), 788-793.

Chan, E. K., Woods, R., Virani, S., Speers, C., Wai, E. S., Nichol, A., McBride, M. L., & Tyldesley, S. (2012). Accelerated hypofractionated versus conventional whole breast radiotherapy for localised left-sided breast cancer: the effect on long-term cardiac morbidity. Cancer Research, 72(24 Suppl 3), Abstract nr PD04-02.

Chan, S. W., Cheung, P. S., & Lam, S. H. (2010). Cosmetic outcome and percentage of breast volume excision in oncoplastic breast conserving surgery. World journal of surgery, 34(7), 1447-52.

Chan, R. J., Teleni, L., McDonald, S., Kelly, J., Mahony, J., Ernst, K., Patford, K., Townsend, J., ... Yates, P. (2020). Breast cancer nursing interventions and clinical effectiveness: a systematic review. BMJ supportive & palliative care, 10(3), 276-286.

Chang, C. C., Elliott, T. A., Wright, G., Shapiro, D. B., Toledo, A. A., & Nagy, Z. P. (2013). Prospective controlled study to evaluate laboratory and clinical outcomes of oocyte vitrification obtained in in vitro fertilization patients aged 30 to 39 years. Fertility and Sterility, 99(7), 1891-7.

Chao, S. T., De Salles, A., Hayashi, M., Levivier, M., Ma, L., Martinez, R., Paddick, I., Régis, J., ... Sahgal, A. (2018). Stereotactic Radiosurgery in the Management of Limited (1-4) Brain Metasteses: Systematic Review and International Stereotactic Radiosurgery Society Practice Guideline. Neurosurgery, 83(3), 345-353.

Chen, J., Zhang, X., Lu, Y., Zhang, T., Ouyang, Z., & Sun, Q. (2021). Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis. Breast Cancer, 28(3), 630-643.

Chlebowski, R. T., Rohan, T. E., Manson, J. E., Aragaki, A. K., Kaunitz, A., Stefanick, M. L., Simon, M. S., Johnson, K. C., ... Prentice, R. L. (2015). Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials. JAMA oncology, 1(3), 296-305.

Chong, A., Weinstein, S. P., McDonald, E. S., & Conant, E. F. (2019). Digital Breast Tomosynthesis: Concepts and Clinical Practice. Radiology, 292(1), 1-14.

Chua, B. H., Link, E. K., Kunkler, I. H., Whelan, T. J., Westenberg, A. H., Gruber, G., Bryant, G., Ahern, V., ... Olivotto, I. A. (2022). Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study. Lancet, 400(10350), 431-440.

Clarke, M., Collins, R., Darby, S., Davies, C., Elphinstone, P., Evans, E., Godwin, J., Gray, R., ... Wang, Y. (2005). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet, 366(9503), 2087-2106.

Clarke, C. N., Cortina, C. S., Fayanju, O. M., Dossett, L. A., Johnston, F. M., & Wong, S. L. (2021). Breast Cancer Risk and Screening in Transgender Persons: A Call for Inclusive Care. Annals of surgical oncology, Jun 7 [epub ahead of print]

Clarke, M. J. (2002). Radiotherapy for early breast cancer. Cochrane database of systematic reviews, (2), CD003647.

Clough, K. B., Lewis, J. S., Couturaud, B., Fitoussi, A., Nos, C., & Falcou, M. C. (2003). Oncoplastic techniques allow extensive resections for breast-conserving therapy of breast carcinomas. Annals of surgery, 237(1), 26-34.

Cloyd, J. M., Hernandez-Boussard, T., & Wapnir, I. L. (2013). Outcomes of partial mastectomy in male breast cancer patients: analysis of SEER, 1983-2009. Annals of surgical oncology, 20(5), 1545-50.

Cluze, C., Rey, D., Huiart, L., BenDiane, M. K., Bouhnik, A. D., Berenger, C., Carrieri, M. P., & Giorgi, R. (2012). Adjuvant endocrine therapy with tamoxifen in young women with breast cancer: determinants of interruptions vary over time. Annals of oncology, 23(4), 882-90.

Coates, A. S., Winer, E. P., Goldhirsch, A., Gelber, R. D., Gnant, M., Piccart-Gebhart, M., Thurlimann, B., & Senn, H. J. (2015). Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Annals of oncology, 26(8), 1533-46.

Coates, A. S., Keshaviah, A., Thurlimann, B., Mouridsen, H., Mauriac, L., Forbes, J. F., Paridaens, R., Castiglione-Gertsch, M., ... Goldhirsch, A. (2007). Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. Journal of clinical oncology, 25(5), 486-492.

Cobo, A., Garcia-Velasco, J., Domingo, J., Pellicer, A., & Remohi, J. (2018). Elective and Onco-fertility preservation: factors related to IVF outcomes. Human reproduction, 33(12), 2222-2231.

Cocco, E., Scaltriti, M., & Drilon, A. (2018). NTRK fusion-positive cancers and TRK inhibitor therapy. Nature reviews. Clinical oncology, 15(12), 731-747.

Cochrane, R. A., Valasiadou, P., Wilson, A. R., Al-Ghazal, S. K., & Macmillan, R. D. (2003). Cosmesis and satisfaction after breast-conserving surgery correlates with the percentage of breast volume excised. The British journal of surgery, 90(12), 1505-9.

Cold, S., During, M., Ewertz, M., Knoop, A., & Møller, S. (2005). Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG). British Journal of Cancer, 93(6), 627-632.

Cold, S., Cold, F., Jensen, M. B., Cronin-Fenton, D., Christiansen, P., & Ejlertsen, B. (2022). Systemic or Vaginal Hormone Therapy After Early Breast Cancer: A Danish Observational Cohort Study. Journal of the National Cancer Institute, 114(10), 1347-1354.

Coleman, R., Finkelstein, D. M., Barrios, C., Martin, M., Iwata, H., Hegg, R., Glaspy, J., Periañez, A. M., ... Chan, A. (2020). Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. The Lancet. Oncology, 21(1), 60-72.

Coleman, R. E., Marshall, H., Cameron, D., Dodwell, D., Burkinshaw, R., Keane, M., Gil, M., Houston, S. J., ... Bell, R. (2011). Breast-cancer adjuvant therapy with zoledronic acid. New England Journal of Medicine, 365(15), 1396-1405.

Coles, C. E., Griffin, C. L., Kirby, A. M., Titley, J., Agrawal, R. K., Alhasso, A., Bhattacharya, I. S., Brunt, A. M., ... Bliss, J. M. (2017). Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet, 390(10099), 1048-1060.

Coles, C. E., Haviland, J. S., Kirby, A. M., Griffin, C. L., Sydenham, M. A., Titley, J. C., Bhattacharya, I., Brunt, A. M., ... Bliss, J. M. (2023). Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial. Lancet, 401(10394), 2124-2137.

Colleoni, M., Bonetti, M., Coates, A. S., Castiglione-Gertsch, M., Gelber, R. D., Price, K., Rudenstam, C. M., Lindtner, J., ... Goldhirsch, A. (2000). Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group. Journal of clinical oncology, 18(3), 584-590.

Collins, L. C., Achacoso, N., Haque, R., Nekhlyudov, L., Fletcher, S. W., Quesenberry, C. P. ,., Schnitt, S. J., & Habel, L. A. (2013). Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ. Breast cancer research and treatment, 139(2), 453-460.

Colwell, A. S., & Taylor, E. M. (2020). Recent Advances in Implant-Based Breast Reconstruction. Plastic and reconstructive surgery, 145(2), 421e-432e.

Conte, P. F., Gennari, A., Landucci, E., & Orlandini, C. (2000). Role of epirubicin in advanced breast cancer. Clinical breast cancer, 1(Suppl 1), S46-S51.

Conte, P., Bisagni, G., Piacentini, F., Sarti, S., Minichillo, S., Anselmi, E., Aieta, M., Gebbia, V., ... Guarneri, V. (2023). Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial. Journal of clinical oncology, 41(32), 4976-4981.

Coombes, R. C., Kilburn, L. S., Snowdon, C. F., Paridaens, R., Coleman, R. E., Jones, S. E., Jassem, J., Van de Velde, C. J., ... Bliss, J. M. (2007). Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet, 369(9561), 559-570.

Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., ... von Minckwitz, G. (2014). Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet, 384(9938), 164-72.

Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., ... Twelves, C. (2011). Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet, 377(9769), 914-923.

Cortes, J., Cescon, D. W., Rugo, H. S., Nowecki, Z., Im, S. A., Yusof, M. M., Gallardo, C., Lipatov, O., ... Schmid, P. (2020). Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet, 396(10265), 1817-1828.

Cortes, J., Kim, S. B., Chung, W. P., Im, S. A., Park, Y. H., Hegg, R., Kim, M. H., Tseng, L. M., ... Hurvitz, S. A. (2021). LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study. Annals of oncology, 32(Suppl 5), S1287-S1288.

Cortes, J., Rugo, H. S., Cescon, D. W., Im, S. A., Yusof, M. M., Gallardo, C., Lipatov, O., Barrios, C. H., ... Schmid, P. (2022). Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine, 387(3), 217-226.

Cortés, J., Kim, S. B., Chung, W. P., Im, S. A., Park, Y. H., Hegg, R., Kim, M. H., Tseng, L. M., ... Hurvitz, S. A. (2022). Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. New England Journal of Medicine, 386(12), 1143-1154.

Cramp, F., & Daniel, J. (2008). Exercise for the management of cancer-related fatigue in adults. Cochrane database of systematic reviews, (2), CD006145.

Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S. A., Masuda, N., Colleoni, M., DeMichele, A., ... Slamon, D. (2016). Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. The Lancet. Oncology, 17(4), 425-39.

Crivellari, D., Aapro, M., Leonard, R., von Minckwitz, G., Brain, E., Goldhirsch, A., Veronesi, A., & Muss, H. (2007). Breast cancer in the elderly. Journal of clinical oncology, 25(14), 1882-1890.

Curigliano, G., Burstein, H. J., E, P. W., Gnant, M., Dubsky, P., Loibl, S., Colleoni, M., Regan, M. M., ... Xu, B. (2017). De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Annals of oncology, 28(8), 1700-1712.

Curigliano, G., Burstein, H. J., Gnant, M., Loibl, S., Cameron, D., Regan, M. M., Denkert, C., Poortmans, P., ... St Gallen Consensus Conference Panelists (2023). Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023. Annals of oncology, 34(11), 970-986.

Curigliano, G., Castelo-Branco, L., Gennari, A., Harbeck, N., Criscitiello, C., Trapani, D. (2025). ESMO ​Metastatic Breast Cancer Living Guideline. [nettdokument]. Lugano: ESMO. Hentet 27.01.2025 fra https://www.esmo.org/living-guidelines/esmo-metastatic-breast-cancer-living-guideline

Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F. (2010). Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. The Lancet. Oncology, 11(12), 1135-1141.

Cuzick, J., Sestak, I., Forbes, J. F., Dowsett, M., Knox, J., Cawthorn, S., Saunders, C., Roche, N., ... Howell, A. (2014). Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet, 383(9922), 1041-8.

Danish Breast Cancer Group (2023). Arvelig mammacancer: henvisningskriterier til genetisk rådgivning, indikation for tilbud om surveillance og profylaktisk kirurgi (Version 2.0). København: DBCG. Hentet fra https://www.dmcg.dk/SysSiteAssets/kliniske-retningslinjer---skabeloner-og-vejledninger/kliniske-retningslinjer-opdelt-pa-dmcg/dbcg/dbcg_arvelig-cancer-mamma_v.2.0_admgodk_02012023.pdf

Darby, S., McGale, P., Correa, C., Taylor, C., Arriagada, R., Clarke, M., Cutter, D., Davies, C., ... Peto, R. (2011). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet, 378(9804), 1707-1716.

Darby, S. C., McGale, P., Taylor, C. W., & Peto, R. (2005). Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. The Lancet. Oncology, 6(8), 557-565.

Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Bronnum, D., Correa, C., Cutter, D., ... Hall, P. (2013). Risk of ischemic heart disease in women after radiotherapy for breast cancer. New England Journal of Medicine, 368(11), 987-998.

Davies, C., Godwin, J., Gray, R., Clarke, M., Cutter, D., Darby, S., McGale, P., Pan, H. C., ... Peto, R. (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet, 378(9793), 771-784.

Davies, C., Pan, H., Godwin, J., Gray, R., Arriagada, R., Raina, V., Abraham, M., Medeiros Alencar, V. H., ... Peto, R. (2013). Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet, 381(9869), 805-816.

de Boer, R., Bundred, N., Eidtmann, H., Neven, P., von Minckwitz, G., Martin, N., ... Modi, A. (2011). Long-Term Survival Outcomes among Postmenopausal Women with Hormone Receptor-Positive Early Breast Cancer Receiving Adjuvant Letrozole and Zoledronic Acid: 5-Year Follow-Up of ZO-FAST. San Antonio: Cancer Therapy & Research Center at UT Health Science Center. Hentet fra http://cancerres.aacrjournals.org/content/71/24_Supplement/S1-3

De La Cruz, L., Blankenship, S. A., Chatterjee, A., Geha, R., Nocera, N., Czerniecki, B. J., Tchou, J., & Fisher, C. S. (2016). Outcomes After Oncoplastic Breast-Conserving Surgery in Breast Cancer Patients: A Systematic Literature Review. Annals of surgical oncology, 23(10), 3247-58.

de Bock, G. H., Bonnema, J., van der Hage, J., Kievit, J., & van de Velde, C. J. (2004). Effectiveness of routine visits and routine tests in detecting isolated locoregional recurrences after treatment for early-stage invasive breast cancer: a meta-analysis and systematic review. Journal of clinical oncology, 22(19), 4010-8.

de Blok, C. J. M., Wiepjes, C. M., Nota, N. M., van Engelen, K., Adank, M. A., Dreijerink, K. M. A., Barbe, E., Konings, I., & den Heijer, M. (2019). Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ, 365, l1652.

de Gregorio, A., Janni, W., Friedl, T. W. P., Nitz, U., Rack, B., Schneeweiss, A., Kates, R., Fehm, T., ... Harbeck, N. (2022). The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C. British Journal of Cancer, 126(12), 1715-1724.

de Mascarel, I., MacGrogan, G., Picot, V., Dougazz, A., & Mathoulin-Pelissier, S. (2006). Results of a long term follow-up study of 115 patients with flat epithelial atypia. Laboratory investigation, 86(Suppl), 25A.

de Boniface, J., Szulkin, R., & Johansson, A. L. V. (2021). Survival After Breast Conservation vs Mastectomy Adjusted for Comorbidity and Socioeconomic Status: A Swedish National 6-Year Follow-up of 48 986 Women. JAMA surgery, 156(7), 628-637.

Del Mastro, L., De Placido, S., Bruzzi, P., De Laurentiis, M., Boni, C., Cavazzini, G., Durando, A., Turletti, A., ... Cognetti, F. (2015). Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 x 2 factorial, randomised phase 3 trial. Lancet, 385(9980), 1863-72.

Del Mastro, L., Boni, L., Michelotti, A., & et al. (2011). Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: A randomized trial. JAMA, 306(3), 269-276.

Del Mastro, L., Bruzzi, P., Nicolo, G., Cavazzini, G., Contu, A., D'Amico, M., Lavarello, A., Testore, F., ... Venturini, M. (2005). HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients. British Journal of Cancer, 93(1), 7-14.

Del Mastro, L., Ceppi, M., Poggio, F., Bighin, C., Peccatori, F., Demeestere, I., Levaggi, A., Giraudi, S., ... Bruzzi, P. (2014). Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: Systematic review and meta-analysis of randomized trials. Cancer Treatment Reviews, 40(5), 675-683.

Delanian, S., Lefaix, J. L., & Pradat, P. F. (2012). Radiation-induced neuropathy in cancer survivors. Radiotherapy and Oncology, 105(3), 273-82.

DeLong, M. R., Tandon, V. J., Bertrand, A. A., MacEachern, M., Goldberg, M., Salibian, A., Pusic, A. L., Festekjian, J. H., & Wilkins, E. G. (2021). Review of Outcomes in Prepectoral Prosthetic Breast Reconstruction with and without Surgical Mesh Assistance. Plastic and reconstructive surgery, 147(2), 305-315.

Demetri, G. D., De Braud, F., Drilon, A., Siena, S., Patel, M. R., Cho, B. C., Liu, S. V., Ahn, M. J., ... Rolfo, C. (2022). Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors. Clinical cancer research, 28(7), 1302-1312.

Denduluri, N., Chavez-MacGregor, M., Telli, M. L., Eisen, A., Graff, S. L., Hassett, M. J., Holloway, J. N., Hurria, A., ... Giordano, S. H. (2018). Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. Journal of clinical oncology, 36(23), 2433-2443.

Deng, G., Vickers, A., Yeung, S., D'Andrea, G. M., Xiao, H., Heerdt, A. S., Sugarman, S., Troso-Sandoval, T., ... Cassileth, B. (2007). Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer patients. Journal of clinical oncology, 25(35), 5584-5590.

Deshpande, N. A., Braun, I. M., & Meyer, F. L. (2015). Impact of fertility preservation counseling and treatment on psychological outcomes among women with cancer: A systematic review. Cancer, 121(22), 3938-3947.

Diaz, R., Degnim, A. C., Boughey, J. C., Nassar, A., & Jakub, J. W. (2012). A positive intramammary lymph node does not mandate a complete axillary node dissection. American journal of surgery, 203(2), 151-155.

Dickler, M. N., Saura, C., Richards, D. A., Krop, I. E., Cervantes, A., Bedard, P. L., Patel, M. R., Pusztai, L., ... Baselga, J. (2018). Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer. Clinical cancer research, 24(18), 4380-4387.

Dickler, M. N., Tolaney, S. M., Rugo, H. S., Cortés, J., Diéras, V., Patt, D., Wildiers, H., Hudis, C. A., ... Baselga, J. (2017). MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR(+)/HER2(-) Metastatic Breast Cancer. Clinical cancer research, 23(17), 5218-5224.

Dieci, M. V., Griguolo, G., Bottosso, M., Tsvetkova, V., Giorgi, C. A., Vernaci, G., Michieletto, S., Angelini, S., ... Guarneri, V. (2021). Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy. NPJ breast cancer, 7(1), 101.

Dijkema, I. M., Hofman, P., Raaijmakers, C. P., Lagendijk, J. J., Battermann, J. J., & Hillen, B. (2004). Loco-regional conformal radiotherapy of the breast: delineation of the regional lymph node clinical target volumes in treatment position. Radiotherapy and Oncology, 71(3), 287-295.

Domchek, S. M., Friebel, T. M., Singer, C. F., Evans, D. G., Lynch, H. T., Isaacs, C., Garber, J. E., Neuhausen, S. L., ... Rebbeck, T. R. (2010). Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA, 304(9), 967-975.

Donegan, W. L., Perez-Mesa, C. M., & Watson, F. R. (1966). A biostatistical study of locally recurrent breast carcinoma. Surgery, gynecology & obstetrics, 122(3), 529-540.

Donker, M., Litière, S., Werutsky, G., Julien, J. P., Fentiman, I. S., Agresti, R., Rouanet, P., de Lara, C. T., ... Bijker, N. (2013). Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. Journal of clinical oncology, 31(32), 4054-9.

Dowsett, M., Forbes, J. F., Bradley, R., Ingle, J., Aihara, T., Bliss, J., Boccardo, F., Coates, A., ... Gray, R. (2015). Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet, 386(10001), 1341-52.

Dowsett, M., Sestak, I., Lopez-Knowles, E., Sidhu, K., Dunbier, A. K., Cowens, J. W., Ferree, S., Storhoff, J., ... Cuzick, J. (2013). Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. Journal of clinical oncology, 31(22), 2783-90.

Dowsett, M., Sestak, I., Regan, M. M., Dodson, A., Viale, G., Thurlimann, B., Colleoni, M., & Cuzick, J. (2018). Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. Journal of clinical oncology, 36(19), 1941-1948.

Duane, F., Aznar, M. C., Bartlett, F., Cutter, D. J., Darby, S. C., Jagsi, R., Lorenzen, E. L., McArdle, O., ... Taylor, C. W. (2017). A cardiac contouring atlas for radiotherapy. Radiotherapy and Oncology, 122(3), 416-422.

Dupont, W. D., & Page, D. L. (1985). Risk factors for breast cancer in women with proliferative breast disease. New England Journal of Medicine, 312(3), 146-151.

Earl, H. M., Hiller, L., Vallier, A. L., Loi, S., McAdam, K., Hughes-Davies, L., Harnett, A. N., Ah-See, M. L., ... Dunn, J. A. (2019). 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet, 393(10191), 2599-2612.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 365(9472), 1687-1717.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2019). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet, 393(10179), 1440-1452.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2023). Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials. Lancet, 401(10384), 1277-1292.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2023). Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials. Lancet, 402(10416), 1991-2003.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2022). Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. The Lancet. Oncology, 23(3), 382-392.

Early Breast Cancer Trialists’ Collaborative group (EBCTCG) (2021). Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials. The Lancet. Oncology, 22(8), 1139-1150.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Correa, C., McGale, P., Taylor, C., Wang, Y., Clarke, M., Davies, C., Peto, R., ... Darby, S. (2010). Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. Journal of the National Cancer Institute Monographs, 2010(41), 162-77.

Eggemann, H., Ignatov, A., Smith, B. J., Altmann, U., von Minckwitz, G., Röhl, F. W., Jahn, M., & Costa, S. D. (2013). Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast cancer research and treatment, 137(2), 465-70.

Eidtmann, H., de Boer, R., Bundred, N., Llombart-Cussac, A., Davidson, N., Neven, P., von Minckwitz, G., Miller, J., ... Coleman, R. (2010). Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Annals of oncology, 21(11), 2188-2194.

Eikesdal, H. P., Løes, S., & Herlofson, B. B. (2014). Tannhelse ved bruk av bisfosfonater mot brystkreft. Tidsskrift for den norske legeforening, 134(15), 1451.

Eisen, A., Somerfield, M. R., Accordino, M. K., Blanchette, P. S., Clemons, M. J., Dhesy-Thind, S., Dillmon, M. S., D'Oronzo, S., ... Van Poznak, C. H. (2022). Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. Journal of clinical oncology, 40(7), 787-800.

Ejlertsen, B., Tuxen, M. K., Jakobsen, E. H., Jensen, M. B., Knoop, A. S., Højris, I., Ewertz, M., Balslev, E., ... Mouridsen, H. T. (2017). Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial. Journal of clinical oncology, 35(23), 2639-2646.

Elgindy, E., Sibai, H., Abdelghani, A., & Mostafa, M. (2015). Protecting Ovaries During Chemotherapy Through Gonad Suppression: A Systematic Review and Meta-analysis. Obstetrics and gynecology, 126(1), 187-95.

Elkins, G., Marcus, J., Stearns, V., & Hasan, R. M. (2007). Pilot evaluation of hypnosis for the treatment of hot flashes in breast cancer survivors. Psychooncology, 16(5), 487-492.

Ellis, M. J., Gao, F., Dehdashti, F., Jeffe, D. B., Marcom, P. K., Carey, L. A., Dickler, M. N., Silverman, P., ... Siegel, B. A. (2009). Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA, 302(7), 774-780.

Elshof, L. E., Schmidt, M. K., Rutgers, E. J. T., van Leeuwen, F. E., Wesseling, J., & Schaapveld, M. (2018). Cause-specific Mortality in a Population-based Cohort of 9799 Women Treated for Ductal Carcinoma In Situ. Annals of surgery, 267(5), 952-958.

Emens, L. A., Adams, S., Barrios, C. H., Diéras, V., Iwata, H., Loi, S., Rugo, H. S., Schneeweiss, A., ... Schmid, P. (2021). First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Annals of oncology, 32(8), 983-993.

Eniu, A., Palmieri, F. M., & Perez, E. A. (2005). Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist, 10(9), 665-685.

Eriksen, E. F., Moen, M. H., & Iversen, O. E. (2018). Østrogener i menopausen – på tide å endre anbefalingene?. Tidsskrift for den norske legeforening, 138(6)

Esteva, F. J., Valero, V., Pusztai, L., Boehnke-Michaud, L., Buzdar, A. U., & Hortobagyi, G. N. (2001). Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist, 6(2), 133-146.

Evans, D. G., Kesavan, N., Lim, Y., Gadde, S., Hurley, E., Massat, N. J., Maxwell, A. J., Ingham, S., ... Duffy, S. W. (2014). MRI breast screening in high-risk women: cancer detection and survival analysis. Breast cancer research and treatment, 145(3), 663-72.

Evans, D. G., Sithambaram, S., van Veen, E. M., Burghel, G. J., Schlecht, H., Harkness, E. F., Byers, H., Ellingford, J. M., ... Woodward, E. R. (2023). Differential involvement of germline pathogenic variants in breast cancer genes between DCIS and low-grade invasive cancers. Journal of medical genetics, 60(8), 740-746.

Fallenberg, E. M., Schmitzberger, F. F., Amer, H., Ingold-Heppner, B., Balleyguier, C., Diekmann, F., Engelken, F., Mann, R. M., ... Dromain, C. (2017). Contrast-enhanced spectral mammography vs. mammography and MRI - clinical performance in a multi-reader evaluation. European radiology, 27(7), 2752-2764.

Falstie-Jensen, A. M., Esen, B., Kjærsgaard, A., Lorenzen, E. L., Jensen, J. D., Reinertsen, K. V., Dekkers, O. M., Ewertz, M., & Cronin-Fenton, D. P. (2020). Incidence of hypothyroidism after treatment for breast cancer-a Danish matched cohort study. Breast cancer research, 22(1), 106.

Faneyte, I. F., Rutgers, E. J., & Zoetmulder, F. A. (1997). Chest wall resection in the treatment of locally recurrent breast carcinoma: indications and outcome for 44 patients. Cancer, 80(5), 886-891.

Farshid, G., & Buckley, E. (2019). Meta-analysis of upgrade rates in 3163 radial scars excised after needle core biopsy diagnosis. Breast cancer research and treatment, 174(1), 165-177.

Fasching, P. A., Schmatloch, S., Hauke, J., Rey, J., Jackisch, C., Klare, P., Link, T., Hanusch, C., ... Loibl, S. (2023). Abstract GS5-02: Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency – long-term survival of the GeparOLA study. Cancer Research, 83(5 Suppl), GS5-02.

Fasching, P. A., Stroyakovskiy, D., Yardley, D., Huang, C. S., Crown, J. P., Bardia, A., Chia, S., Im, S. A., ... Hurvitz, S. A. (2024). LBA13 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+/HER2- early breast cancer (EBC): 4-year outcomes from the NATALEE trial. Annals of Oncology, 35(Suppl 2), S1207.

Feliciano, Y., Mamtani, A., Morrow, M., Stempel, M. M., Patil, S., & Jochelson, M. S. (2017). Do Calcifications Seen on Mammography After Neoadjuvant Chemotherapy for Breast Cancer Always Need to Be Excised?. Annals of surgical oncology, 24(6), 1492-1498.

Ferguson, T., Wilcken, N., Vagg, R., Ghersi, D., & Nowak, A. K. (2007). Taxanes for adjuvant treatment of early breast cancer. Cochrane database of systematic reviews, (4), CD004421.

Filipits, M., Nielsen, T. O., Rudas, M., Greil, R., Stoger, H., Jakesz, R., Bago-Horvath, Z., Dietze, O., ... Gnant, M. (2014). The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clinical cancer research, 20(5), 1298-305.

Finch, A. P., Lubinski, J., Moller, P., Singer, C. F., Karlan, B., Senter, L., Rosen, B., Maehle, L., ... Narod, S. A. (2014). Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. Journal of clinical oncology, 32(15), 1547-53.

Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., ... Slamon, D. J. (2014). Abstract CT101: Final results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18). Cancer Research, 74(19 Suppl), CT101.

Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., ... Slamon, D. J. (2015). The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. The Lancet. Oncology, 16(1), 25-35.

Finn, R. S., Rugo, H. S., Dieras, V. C., Harbeck, N., Im, S., Gelmon, K. A., Walshe, J. M., Martin, M., ... Slamon, D. J. (2022). Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2. Journal of clinical oncology, 40(17_suppl), LBA1003.

Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S. A., Gelmon, K., Harbeck, N., Lipatov, O. N., ... Slamon, D. J. (2016). Palbociclib and Letrozole in Advanced Breast Cancer. New England Journal of Medicine, 375(20), 1925-1936.

Fisher, B., Dignam, J., Wolmark, N., Mamounas, E., Costantino, J., Poller, W., Fisher, E. R., Wickerham, D. L., ... Kavanah, M. (1998). Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. Journal of clinical oncology, 16(2), 441-52.

Fisher, B., Ravdin, R. G., Ausman, R. K., Slack, N. H., Moore, G. E., & Noer, R. J. (1968). Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation. Annals of surgery, 168(3), 337-356.

Fisher, B., Land, S., Mamounas, E., Dignam, J., Fisher, E. R., & Wolmark, N. (2001). Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Seminars in oncology, 28(4), 400-418.

Fisher, B., Anderson, S., Bryant, J., Margolese, R. G., Deutsch, M., Fisher, E. R., Jeong, J. H., & Wolmark, N. (2002). Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. New England Journal of Medicine, 347(16), 1233-1241.

Flemming, J., Madarnas, Y., & Franek, J. A. (2009). Fulvestrant for systemic therapy of locally advanced or metastatic breast cancer in postmenopausal women: a systematic review. Breast cancer research and treatment, 115(2), 255-268.

Fontein, D. B., van de Water, W., Mieog, J. S., Liefers, G. J., & Van de Velde, C. J. (2013). Timing of the sentinel lymph node biopsy in breast cancer patients receiving neoadjuvant therapy - recommendations for clinical guidance. European journal of surgical oncology, 39(5), 417-424.

Forbes, J. F., Cuzick, J., Buzdar, A., Howell, A., Tobias, J. S., & Baum, M. (2008). Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. The Lancet. Oncology, 9(1), 45-53.

Forester, N. D., Lowes, S., Mitchell, E., & Twiddy, M. (2019). High risk (B3) breast lesions: What is the incidence of malignancy for individual lesion subtypes? A systematic review and meta-analysis. European journal of surgical oncology, 45(4), 519-527.

Forsythe, A., Zhang, W., Phillip Strauss, U., Fellous, M., Korei, M., & Keating, K. (2020). A systematic review and meta-analysis of neurotrophic tyrosine receptor kinase gene fusion frequencies in solid tumors. Therapeutic advances in medical oncology, 12, 1.758835920975613E15.

Fortuno, C., James, P. A., & Spurdle, A. B. (2018). Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome. Human mutation, 39(12), 1764-1773.

Fountzilas, G., Athanassiades, A., Giannakakis, T., Briasoulis, E., Bafaloukos, D., Kalogera-Fountzila, A., Onienaoum, A., Kalofonos, H., ... Skarlos, D. (1997). A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study. Annals of oncology, 8(12), 1213-1220.

Francis, P., Crown, J., Di, L. A., Buyse, M., Balil, A., Andersson, M., Nordenskjold, B., Lang, I., ... Piccart-Gebhart, M. (2008). Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. Journal of the National Cancer Institute, 100(2), 121-133.

Francis, P. A., Fleming, G. F., Láng, I., Ciruelos, E. M., Bonnefoi, H. R., Bellet, M., Bernardo, A., Climent, M. A., ... Regan, M. M. (2023). Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. Journal of clinical oncology, 41(7), 1370-1375.

Francis, P. A., Pagani, O., Fleming, G. F., Walley, B. A., Colleoni, M., Lang, I., Gomez, H. L., Tondini, C., ... Regan, M. M. (2018). Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. New England Journal of Medicine, 379(2), 122-137.

Francis, P. A., Regan, M. M., Fleming, G. F., Lang, I., Ciruelos, E., Bellet, M., Bonnefoi, H. R., Climent, M. A., ... Gelber, R. D. (2015). Adjuvant ovarian suppression in premenopausal breast cancer. New England Journal of Medicine, 372(5), 436-46.

Franzoi, M. A., Agostinetto, E., Perachino, M., Del Mastro, L., de Azambuja, E., Vaz-Luis, I., Partridge, A. H., & Lambertini, M. (2021). Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. The Lancet. Oncology, 22(7), e303-e313.

Frebourg, T., Bajalica Lagercrantz, S., Oliveira, C., Magenheim, R., & Evans, D. G. (2020). Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes. European journal of human genetics : EJHG, 28(10), 1379-1386.

Frederick, M. J., Lin, A. M., Neuman, R., Smith, B. L., Austen, W. G. ,. J., & Colwell, A. S. (2015). Nipple-sparing mastectomy in patients with previous breast surgery: comparative analysis of 775 immediate breast reconstructions. Plastic and reconstructive surgery, 135(6), 954e-962e.

Frey, J. D., Salibian, A. A., Choi, M., & Karp, N. S. (2020). Putting Together the Pieces: Development and Validation of a Risk-Assessment Model for Nipple-Sparing Mastectomy. Plastic and reconstructive surgery, 145(2), 273e-283e.

Fribbens, C., O'Leary, B., Kilburn, L., Hrebien, S., Garcia-Murillas, I., Beaney, M., Cristofanilli, M., Andre, F., ... Turner, N. C. (2016). Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. Journal of clinical oncology, 34(25), 2961-8.

Friedl, T. W. P., Fehm, T., Müller, V., Lichtenegger, W., Blohmer, J., Lorenz, R., Forstbauer, H., Fink, V., ... Rack, B. (2021). Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial. JAMA oncology, 7(8), 1149-1157.

Friedrich, M. (1998). MRI of the breast: state of the art. European radiology, 8(5), 707-25.

Fritz, H., Seely, D., Flower, G., Skidmore, B., Fernandes, R., Vadeboncoeur, S., Kennedy, D., Cooley, K., ... Fergusson, D. (2013). Soy, red clover, and isoflavones and breast cancer: a systematic review. PLoS ONE, 8(11), e81968.

Froud, P. J., Mates, D., Jackson, J. S., Phillips, N., Andersen, S., Jackson, S. M., Bryce, C. J., & Olivotto, I. A. (2000). Effect of time interval between breast-conserving surgery and radiation therapy on ipsilateral breast recurrence. International journal of radiation oncology, biology, physics, 46(2), 363-372.

Furet, E., Peurien, D., Fournier-Bidoz, N., Servois, V., Reyal, F., Fourquet, A., Rouzier, R., & Kirova, Y. M. (2014). Plastic surgery for breast conservation therapy: how to define the volume of the tumor bed for the boost?. European journal of surgical oncology, 40(7), 830-4.

Galimberti, V., Botteri, E., Chifu, C., Gentilini, O., Luini, A., Intra, M., Baratella, P., Sargenti, M., ... Veronesi, U. (2012). Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer?. Breast cancer research and treatment, 131(3), 819-825.

Gao, J. J., Cheng, J., Prowell, T. M., Bloomquist, E., Tang, S., Wedam, S. B., Royce, M., Krol, D., ... Amiri-Kordestani, L. (2021). Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis. The Lancet. Oncology, 22(11), 1573-1581.

Gao, C., Polley, E. C., Hart, S. N., Huang, H., Hu, C., Gnanaolivu, R., Lilyquist, J., Boddicker, N. J., ... Kraft, P. (2021). Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score. Journal of clinical oncology, 39(23), 2564-2573.

Garreffa, E., Hughes-Davies, L., Russell, S., Lightowlers, S., & Agrawal, A. (2020). Definition of Tumor Bed Boost in Oncoplastic Breast Surgery: An Understanding and Approach. Clinical breast cancer, S1526-8209(20)30059-8 [epub ahead of print]

Gasparini, G., Gion, M., Mariani, L., Papaldo, P., Crivellari, D., Filippelli, G., Morabito, A., Silingardi, V., ... Amadori, D. (2007). Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast cancer research and treatment, 101(3), 355-365.

Gennari, A., André, F., Barrios, C. H., Cortés, J., de Azambuja, E., DeMichele, A., Dent, R., Fenlon, D., ... Harbeck, N. (2021). ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Annals of oncology, 32(12), 1475-1495.

Gentile, P., & Cervelli, V. (2022). Systematic review: Oncological safety of reconstruction with fat grafting in breast cancer outcomes. Journal of plastic, reconstructive & aesthetic surgery : JPRAS,

Gentile, P., Bernini, M., Orzalesi, L., Sordi, S., Meattini, I., Lessi, F., Kothari, A., & Calabrese, C. (2021). Titanium-coated polypropylene mesh as innovative bioactive material in conservatives mastectomies and pre-pectoral breast reconstruction. Bioactive Materials, 6(12), 4640-4653.

Geyer, C. E. ,. J., Garber, J. E., Gelber, R. D., Yothers, G., Taboada, M., Ross, L., Rastogi, P., Cui, K., ... Tutt, A. N. J. (2022). Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Annals of oncology, 33(12), 1250-1268.

Geyer, C. E., Sikov, W. M., Huober, J., Rugo, H. S., Wolmark, N., O'Shaughnessy, J., Maag, D., Untch, M., ... Loibl, S. (2022). Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial. Annals of oncology, 33(4), 384-394.

Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., ... Cameron, D. (2006). Lapatinib plus capecitabine for HER2-positive advanced breast cancer. New England Journal of Medicine, 355(26), 2733-2743.

Ghersi, D., Wilcken, N., Simes, J., & Donoghue, E. (2005). Taxane containing regimens for metastatic breast cancer. Cochrane database of systematic reviews, (2), CD003366.

Giannakeas, V., & Narod, S. A. (2018). The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy. Breast cancer research and treatment, 167(1), 263-267.

Giannakeas, V., Sopik, V., & Narod, S. A. (2020). Association of a Diagnosis of Ductal Carcinoma In Situ With Death From Breast Cancer. JAMA network open, 3(9), e2017124.

Gianni, L., Pienkowski, T., Im, Y. H., Tseng, L. M., Liu, M. C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., ... Valagussa, P. (2016). 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. The Lancet. Oncology, 17(6), 791-800.

Gianni, L., Mansutti, M., Anton, A., Calvo, L., Bisagni, G., Bermejo, B., Semiglazov, V., Thill, M., ... Tusquets, I. (2018). Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer-The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial. JAMA oncology, 4(3), 302-308.

Gibson, L., Lawrence, D., Dawson, C., & Bliss, J. (2009). Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane database of systematic reviews, (4), CD003370.

Gilliland, M. D., Barton, R. M., & Copeland, E. M. ,. 3. (1983). The implications of local recurrence of breast cancer as the first site of therapeutic failure. Annals of surgery, 197(3), 284-287.

Giltnane, J. M., Hutchinson, K. E., Stricker, T. P., Formisano, L., Young, C. D., Estrada, M. V., Nixon, M. J., Du, L., ... Arteaga, C. L. (2017). Genomic profiling of ER(+) breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Science translational medicine, 9(402), eaai7993.

Giordano, S. H., Kuo, Y. F., Freeman, J. L., Buchholz, T. A., Hortobagyi, G. N., & Goodwin, J. S. (2005). Risk of cardiac death after adjuvant radiotherapy for breast cancer. Journal of the National Cancer Institute, 97(6), 419-424.

Giordano, S. H., Temin, S., Kirshner, J. J., Chandarlapaty, S., Crews, J. R., Davidson, N. E., Esteva, F. J., Gonzalez-Angulo, A. M., ... Winer, E. P. (2014). Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. Journal of clinical oncology, 32(19), 2078-99.

Giuliano, A. E., Hunt, K. K., Ballman, K. V., Beitsch, P. D., Whitworth, P. W., Blumencranz, P. W., Leitch, A. M., Saha, S., ... Morrow, M. (2011). Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA, 305(6), 569-575.

Giuliano, A. E., Ballman, K. V., McCall, L., Beitsch, P. D., Brennan, M. B., Kelemen, P. R., Ollila, D. W., Hansen, N. M., ... Morrow, M. (2017). Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA, 318(10), 918-926.

Giuliano, A. E., McCall, L., Beitsch, P., Whitworth, P. W., Blumencranz, P., Leitch, A. M., Saha, S., Hunt, K. K., ... Ballman, K. (2010). Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Annals of surgery, 252(3), 426-432.

Glaser, R., & Dimitrakakis, C. (2015). Testosterone and breast cancer prevention. Maturitas, 82(3), 291-5.

Gluz, O., Nitz, U. A., Christgen, M., Kates, R. E., Shak, S., Clemens, M., Kraemer, S., Aktas, B., ... Harbeck, N. (2016). West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment. Journal of clinical oncology, 34(20), 2341-9.

Gnant, M., Mlineritsch, B., Luschin-Ebengreuth, G., Stoeger, H., Dubsky, P., Jakesz, R., ... Singer, C. (2011). Long-Term Follow-Up in ABCSG-12: Significantly Improved Overall Survival with Adjuvant Zoledronic Acid in Premenopausal Patients with Endocrine-Receptor-Positive Early Breast Cancer. San Antonio: Cancer Therapy & Research Center at UT Health Science Center. Hentet fra http://cancerres.aacrjournals.org/content/71/24_Supplement/S1-2

Gnant, M., Sestak, I., Filipits, M., Dowsett, M., Balic, M., Lopez-Knowles, E., Greil, R., Dubsky, P., ... Cuzick, J. (2015). Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. Annals of oncology, 26(8), 1685-91.

Gnant, M., Dueck, A. C., Frantal, S., Martin, M., Burstein, H. J., Greil, R., Fox, P., Wolff, A. C., ... Mayer, E. L. (2022). Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). Journal of clinical oncology, 40(3), 282-293.

Gnant, M., Mlineritsch, B., Stoeger, H., Luschin-Ebengreuth, G., Heck, D., Menzel, C., Jakesz, R., Seifert, M., ... Greil, R. (2011). Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. The Lancet. Oncology, 12(7), 631-641.

Gnant, M., Frantal, S., Pfeiler, G., Steger, G. G., Egle, D., Greil, R., Fitzal, F., Wette, V., ... Singer, C. F. (2022). Long-term outcomes of adjuvant denosumab in breast cancer: Fracture reduction and survival results from 3,425 patients in the randomised, double-blind, placebo-controlled ABCSG-18 trial. Journal of clinical oncology, 40(16_suppl), 507.

Gnant, M., Fitzal, F., Rinnerthaler, G., Steger, G. G., Greil-Ressler, S., Balic, M., Heck, D., Jakesz, R., ... Greil, R. (2021). Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. New England Journal of Medicine, 385(5), 395-405.

Gnant, M., Mlineritsch, B., Schippinger, W., Luschin-Ebengreuth, G., Postlberger, S., Menzel, C., Jakesz, R., Seifert, M., ... Marth, C. (2009). Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New England Journal of Medicine, 360(7), 679-691.

Goetz, M. P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I. H., Trédan, O., ... Di Leo, A. (2017). MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. Journal of clinical oncology, 35(32), 3638-3646.

Goetz, M. P., Knox, S. K., Suman, V. J., Rae, J. M., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., ... Ingle, J. N. (2007). The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast cancer research and treatment, 101(1), 113-121.

Goldgar, D. E., Healey, S., Dowty, J. G., Da Silva, L., Chen, X., Spurdle, A. B., Terry, M. B., Daly, M. J., ... Chenevix-Trench, G. (2011). Rare variants in the ATM gene and risk of breast cancer. Breast cancer research, 13(4), R73.

Goldhirsch, A., Gelber, R. D., Piccart-Gebhart, M. J., de Azambuja, E., Procter, M., Suter, T. M., Jackisch, C., Cameron, D., ... Baselga, J. (2013). 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet, 382(9897), 1021-8.

Goldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S., Thurlimann, B., & Senn, H. J. (2005). Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Annals of oncology, 16(10), 1569-1583.

Goldhirsch, A., Ingle, J. N., Gelber, R. D., Coates, A. S., Thurlimann, B., & Senn, H. J. (2009). Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Annals of oncology, 20(8), 1319-1329.

Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thurlimann, B., & Senn, H. J. (2013). Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of oncology, 24(9), 2206-2223.

Goldhirsch, A., Wood, W. C., Coates, A. S., Gelber, R. D., Thurlimann, B., & Senn, H. J. (2011). Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Annals of oncology, 22(8), 1736-1747.

Goldhirsch, A., Wood, W. C., Gelber, R. D., Coates, A. S., Thurlimann, B., & Senn, H. J. (2007). Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Annals of oncology, 18(7), 1133-1144.

Gompel, A., Sirmoachkova, M., Lombet, A., Thevenin, D., Mimoun, M., & Poitout, P. (1997). The effect of tibolone on proliferation, differentiation and apoptosis in normal breast cells. Gynecological Endocrinology, 11(Suppl 1), 77-79.

Gonzalez, V., Sandelin, K., Karlsson, A., Aberg, W., Lofgren, L., Iliescu, G., Eriksson, S., & Arver, B. (2014). Preoperative MRI of the breast (POMB) influences primary treatment in breast cancer: a prospective, randomized, multicenter study. World journal of surgery, 38(7), 1685-93.

Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Livingston, R. B., Davidson, N. E., Perez, E. A., ... Tu, D. (2013). Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Annals of oncology, 24(2), 355-361.

Goss, P. E., Ingle, J. N., Pritchard, K. I., Robert, N. J., Muss, H., Gralow, J., Gelmon, K., Whelan, T., ... Parulekar, W. R. (2016). Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. New England Journal of Medicine, 375(3), 209-19.

Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005). Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. Journal of clinical oncology, 23(31), 7794-803.

Gradishar, W. J., Krasnojon, D., Cheporov, S., Makhson, A. N., Manikhas, G. M., Clawson, A., & Bhar, P. (2009). Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. Journal of clinical oncology, 27(22), 3611-3619.

Gravina, P. R., Pettit, R. W., Davis, M. J., Winocour, S. J., & Selber, J. C. (2019). Evidence for the Use of Acellular Dermal Matrix in Implant-Based Breast Reconstruction. Seminars in plastic surgery, 33(4), 229-235.

Gray, R., Rea, D., Handley, K., Bowden, S. J., Perry, P., Earl, H. M., Poole, C. J., Bates, T., ... al., e. (2013). aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer.. Journal of clinical oncology, 31(suppl - abstr 5)

Greenlee, H., Iribarren, C., Rana, J. S., Cheng, R., Nguyen-Huynh, M., Rillamas-Sun, E., Shi, Z., Laurent, C. A., ... Kwan, M. L. (2022). Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study. Journal of clinical oncology, 40(15), 1647-1658.

Gregory, W., Marshall, H., Bell, R., Cameron, D. A., & Coleman, R. E. (2012). Adjuvant zoledronic acid (ZOL) in postmenopausal women with breast cancer and those rendered postmenopausal: Results of a meta-analysis. Journal of clinical oncology, 30(15 Supplement), 513.

Griepsma, M., de Roy van Zuidewijn, D. B., Grond, A. J., Siesling, S., Groen, H., & de Bock, G. H. (2014). Residual breast tissue after mastectomy: how often and where is it located?. Annals of surgical oncology, 21(4), 1260-6.

Grindedal, E. M., Heramb, C., Karsrud, I., Ariansen, S. L., Maehle, L., Undlien, D. E., Norum, J., & Schlichting, E. (2017). Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers. BMC Cancer, 17(1), 438.

Grogan, M., Tabar, L., Chua, B., Chen, H. H., & Boyages, J. (2001). Estimating the benefits of adjuvant systemic therapy for women with early breast cancer. The British journal of surgery, 88(11), 1513-1518.

Groheux, D., Vaz, S. C., Poortmans, P., Mann, R. M., Ulaner, G. A., Cook, G. J. R., Hindié, E., Pilkington Woll, J. P., ... Cardoso, F. (2024). . Breast, 78, 103806.

Gundersen, S., Kvinnsland, S., Klepp, O., Kvaloy, S., Lund, E., & Host, H. (1986). Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial. European journal of cancer & clinical oncology, 22(12), 1431-1434.

Gundersen, S., Hannisdal, E., Lundgren, S., & Wist, E. (1994). Weekly doxorubicin with or without high-dose medroxyprogesterone acetate in hormone-resistant advanced breast cancer. A randomised study. The Norwegian Breast Cancer Group. European journal of cancer, 30A(12), 1775-1778.

Gupta, S., Nair, N. S., Hawaldar, R., Vanmali, V., Parmar, V., Gulia, S., Ghosh, J., Joshi, S., ... Badwe, R. (2023). Abstract GS5-01: Addition of platinum to sequential taxane-anthracycline neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial. Cancer Research, 83(5 Suppl), GS5-01.

Gøtzsche, P. C., & Nielsen, M. (2011). Screening for breast cancer with mammography. Cochrane database of systematic reviews, (1), CD001877.

Habberstad, R., Frøseth, T. C. S., Aass, N., Bjerkeset, E., Abramova, T., Garcia-Alonso, E., Caputo, M., Rossi, R., ... Klepstad, P. (2021). Clinical Predictors for Analgesic Response to Radiotherapy in Patients with Painful Bone Metastases. Journal of pain and symptom management, 62(4), 681-690.

Halverson, K. J., Perez, C. A., Kuske, R. R., Garcia, D. M., Simpson, J. R., & Fineberg, B. (1990). Isolated local-regional recurrence of breast cancer following mastectomy: radiotherapeutic management. International journal of radiation oncology, biology, physics, 19(4), 851-858.

Hamdi, M., Spano, A., Van Landuyt, K., D'Herde, K., Blondeel, P., & Monstrey, S. (2008). The lateral intercostal artery perforators: anatomical study and clinical application in breast surgery. Plastic and reconstructive surgery, 121(2), 389-96.

Hancock, S. L., Cox, R. S., & McDougall, I. R. (1991). Thyroid diseases after treatment of Hodgkin's disease. New England Journal of Medicine, 325(9), 599-605.

Hannoun-Levi, J. M., Resch, A., Gal, J., Kauer-Dorner, D., Strnad, V., Niehoff, P., Loessl, K., Kovács, G., ... Polgár, C. (2013). Accelerated partial breast irradiation with interstitial brachytherapy as second conservative treatment for ipsilateral breast tumour recurrence: multicentric study of the GEC-ESTRO Breast Cancer Working Group. Radiotherapy and Oncology, 108(2), 226-31.

Hanrahan, E. O., Valero, V., Gonzalez-Angulo, A. M., & Hortobagyi, G. N. (2006). Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature. Journal of clinical oncology, 24(13), 2113-2122.

Hanson, H., Astiazaran-Symonds, E., Amendola, L. M., Balmana, J., Foulkes, W. D., James, P., Klugman, S., Ngeow, J., ... Guidelines Committee. Electronic address, d. a. n. (2023). Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genetics in medicine, 25(10), 100870.

Harbeck, N., Rastogi, P., Martin, M., Tolaney, S. M., Shao, Z. M., Fasching, P. A., Huang, C. S., Jaliffe, G. G., ... O'Shaughnessy, J. (2021). Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Annals of oncology, 32(12), 1571-1581.

Harbeck, N., Nitz, U. A., Christgen, M., Kümmel, S., Braun, M., Schumacher, C., Potenberg, J., Tio, J., ... Gluz, O. (2023). De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial. Journal of clinical oncology, 41(22), 3796-3804.

Harbeck, N., Ciruelos, E., Jerusalem, G., Müller, V., Niikura, N., Viale, G., Bartsch, R., Kurzeder, C., ... Lin, N. U. (2024). Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial. Nature medicine, 30(12), 3717-3727.

Harris, L., Batist, G., Belt, R., Rovira, D., Navari, R., Azarnia, N., Welles, L., & Winer, E. (2002). Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer, 94(1), 25-36.

Harris, L. N., Ismaila, N., McShane, L. M., Andre, F., Collyar, D. E., Gonzalez-Angulo, A. M., Hammond, E. H., Kuderer, N. M., ... Hayes, D. F. (2016). Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of clinical oncology, 34(10), 1134-50.

Hartmann, L. C., Sellers, T. A., Schaid, D. J., Frank, T. S., Soderberg, C. L., Sitta, D. L., Frost, M. H., Grant, C. S., ... Jenkins, R. B. (2001). Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. Journal of the National Cancer Institute, 93(21), 1633-7.

Harvey, J. A., Mahoney, M. C., Newell, M. S., Bailey, L., Barke, L. D., D'Orsi, C., Hayes, M. K., Jokich, P. M., ... Haffty, B. G. (2016). ACR Appropriateness Criteria Palpable Breast Masses. Journal of the American College of Radiology : JACR, 13(11s), e31-e42.

Hassett, M. J., Somerfield, M. R., Baker, E. R., Cardoso, F., Kansal, K. J., Kwait, D. C., Plichta, J. K., Ricker, C., ... Giordano, S. H. (2020). Management of Male Breast Cancer: ASCO Guideline. Journal of clinical oncology, 38(16), 1849-1863.

Haviland, J. S., Owen, J. R., Dewar, J. A., Agrawal, R. K., Barrett, J., Barrett-Lee, P. J., Dobbs, H. J., Hopwood, P., ... Yarnold, J. R. (2013). The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. The Lancet. Oncology, 14(11), 1086-1094.

Hayes, D. F., & Rae, J. M. (2020). Pharmacogenomics and Endocrine Therapy in Breast Cancer. Journal of clinical oncology, 38(6), 525-528.

Hayes, D. F., Thor, A. D., Dressler, L. G., Weaver, D., Edgerton, S., Cowan, D., Broadwater, G., Goldstein, L. J., ... Berry, D. A. (2007). HER2 and response to paclitaxel in node-positive breast cancer. New England Journal of Medicine, 357(15), 1496-1506.

Haylock, B. J., Coppin, C. M., Jackson, J., Basco, V. E., & Wilson, K. S. (2000). Locoregional first recurrence after mastectomy: prospective cohort studies with and without immediate chemotherapy. International journal of radiation oncology, biology, physics, 46(2), 355-362.

He, W., Grassmann, F., Eriksson, M., Eliasson, E., Margolin, S., Thoren, L., Hall, P., & Czene, K. (2020). CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer. Journal of clinical oncology, 38(6), 548-557.

Helsten, T., Elkin, S., Arthur, E., Tomson, B. N., Carter, J., & Kurzrock, R. (2016). The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing. Clinical cancer research, 22(1), 259-67.

Hendricks, L. A. J., Hoogerbrugge, N., Mensenkamp, A. R., Brunet, J., Lleuger-Pujol, R., Hoberg-Vetti, H., Tveit Haavind, M., Innella, G., ... Vos, J. R. (2023). Cancer risks by sex and variant type in PTEN hamartoma tumor syndrome. Journal of the National Cancer Institute, 115(1), 93-103.

Hennequin, C., Bossard, N., Servagi-Vernat, S., Maingon, P., Dubois, J. B., Datchary, J., Carrie, C., Roullet, B., ... Romestaing, P. (2013). Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy. International journal of radiation oncology, biology, physics, 86(5), 860-6.

Henry, N. L., Unger, J. M., Schott, A. F., Fehrenbacher, L., Flynn, P. J., Prow, D. M., Sharer, C. W., Burton, G. V., ... Wade, J. L. ,. 3. (2018). Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. Journal of clinical oncology, 36(4), 326-332.

Hershman, D. L., Kushi, L. H., Shao, T., Buono, D., Kershenbaum, A., Tsai, W. Y., Fehrenbacher, L., Gomez, S. L., ... Neugut, A. I. (2010). Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. Journal of clinical oncology, 28(27), 4120-8.

Hickey, M., Saunders, C., Partridge, A., Santoro, N., Joffe, H., & Stearns, V. (2008). Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Annals of oncology, 19(10), 1669-1680.

Hickey, B. E., Francis, D., & Lehman, M. H. (2006). Sequencing of chemotherapy and radiation therapy for early breast cancer. Cochrane database of systematic reviews, (4), CD005212.

Hillner, B. E., Ingle, J. N., Berenson, J. R., Janjan, N. A., Albain, K. S., Lipton, A., Yee, G., Biermann, J. S., ... Pfister, D. G. (2000). American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. Journal of clinical oncology, 18(6), 1378-1391.

Himelstein, A. L., Qin, R., Novotny, P. J., Seisler, D. K., Khatcheressian, J. L., Roberts, J. D., & Grubbs, S. S. (2015). A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer. Journal of clinical oncology, 33(15 suppl), abstract 9501.

Hoberg-Vetti, H., Bjorvatn, C., Fiane, B. E., Aas, T., Woie, K., Espelid, H., Rusken, T., Eikesdal, H. P., ... Hoogerbrugge, N. (2016). BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study. European journal of human genetics : EJHG, 24(6), 881-8.

Hofvind, S., Ursin, G., Tretli, S., Sebuødegård, S., & Møller, B. (2013). Breast cancer mortality in participants of the Norwegian Breast Cancer Screening Program. Cancer, 119(17), 3106-3112.

Holmberg, L., Garmo, H., Granstrand, B., Ringberg, A., Arnesson, L. G., Sandelin, K., Karlsson, P., Anderson, H., & Emdin, S. (2008). Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast. Journal of clinical oncology, 26(8), 1247-52.

Holmberg, L., Iversen, O. E., Rudenstam, C. M., Hammar, M., Kumpulainen, E., Jaskiewicz, J., Jassem, J., Dobaczewska, D., ... Maenpaa, J. (2008). Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. Journal of the National Cancer Institute, 100(7), 475-482.

Hoogstraten, B., Gad-el-Mawla, N., Maloney, T. R., Fletcher, W. S., Vaughn, C. B., Tranum, B. L., Athens, J. W., Costanzi, J. J., & Foulkes, M. (1984). Combined modality therapy for first recurrence of breast cancer. A Southwest Oncology Group study. Cancer, 54(10), 2248-2256.

Hörner-Rieber, J., Forster, T., Hommertgen, A., Haefner, M. F., Arians, N., König, L., Harrabi, S. B., Schlampp, I., ... Debus, J. (2021). Intensity Modulated Radiation Therapy (IMRT) With Simultaneously Integrated Boost Shortens Treatment Time and Is Noninferior to Conventional Radiation Therapy Followed by Sequential Boost in Adjuvant Breast Cancer Treatment: Results of a Large Randomized Phase III Trial (IMRT-MC2 Trial). International journal of radiation oncology, biology, physics, 109(5), 1311-1324.

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Petrakova, K., ... O'Shaughnessy, J. (2018). Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Annals of oncology, 29(7), 1541-1547.

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Hart, L., Campone, M., Petrakova, K., ... O'Shaughnessy, J. (2022). Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. New England Journal of Medicine, 386(10), 942-950.

Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., ... O'Shaughnessy, J. (2016). Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. New England Journal of Medicine, 375(18), 1738-1748.

Hortobagyi, G. N., Theriault, R. L., Porter, L., Blayney, D., Lipton, A., Sinoff, C., Wheeler, H., Simeone, J. F., ... Knight, R. D. (1996). Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. New England Journal of Medicine, 335(24), 1785-1791.

Houghton, J., George, W. D., Cuzick, J., Duggan, C., Fentiman, I. S., & Spittle, M. (2003). Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet, 362(9378), 95-102.

Houssami, N., Turner, R., & Morrow, M. (2013). Preoperative magnetic resonance imaging in breast cancer: meta-analysis of surgical outcomes. Annals of surgery, 257(2), 249-55.

Houssami, N., Macaskill, P., Marinovich, M. L., Dixon, J. M., Irwig, L., Brennan, M. E., & Solin, L. J. (2010). Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy. European journal of cancer, 46(18), 3219-3232.

Houssami, N., Macaskill, P., von Minckwitz, G., Marinovich, M. L., & Mamounas, E. (2012). Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. European journal of cancer, 48(18), 3342-54.

Hu, C., Hart, S. N., Gnanaolivu, R., Huang, H., Lee, K. Y., Na, J., Gao, C., Lilyquist, J., ... Couch, F. J. (2021). A Population-Based Study of Genes Previously Implicated in Breast Cancer. New England Journal of Medicine, 384(5), 440-451.

Huang, E. H., Tucker, S. L., Strom, E. A., McNeese, M. D., Kuerer, H. M., Buzdar, A. U., Valero, V., Perkins, G. H., ... Buchholz, T. A. (2004). Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. Journal of clinical oncology, 22(23), 4691-4699.

Hugh, J., Hanson, J., Cheang, M. C., Nielsen, T. O., Perou, C. M., Dumontet, C., Reed, J., Krajewska, M., ... Vogel, C. (2009). Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. Journal of clinical oncology, 27(8), 1168-1176.

Hughes, R. T., Masters, A. H., McTyre, E. R., Farris, M. K., Chung, C., Page, B. R., Kleinberg, L. R., Hepel, J., ... Chan, M. D. (2019). Initial SRS for Patients With 5 to 15 Brain Metastases: Results of a Multi-Institutional Experience. International journal of radiation oncology, biology, physics, 104(5), 1091-1098.

Hunt, K. K., Yi, M., Mittendorf, E. A., Guerrero, C., Babiera, G. V., Bedrosian, I., Hwang, R. F., Kuerer, H. M., ... Meric-Bernstam, F. (2009). Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Annals of surgery, 250(4), 558-566.

Huober, J., Weder, P., Ribi, K., Thürlimann, B., Thery, J. C., Li, Q., Vanlemmens, L., Guiu, S., ... Bonnefoi, H. (2023). Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA oncology, 9(10), 1381-1389.

Hurvitz, S., Kim, S., Chung, W., Im, S., Park, Y. H., Hegg, R., Kim, M., Tseng, L., ... Cortés, J. (2022). Abstract GS3-01: Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03. Cancer Research, 82(4 Suppl), GS3-01.

Hurvitz, S. A., Hegg, R., Chung, W. P., Im, S. A., Jacot, W., Ganju, V., Chiu, J. W. Y., Xu, B., ... Cortés, J. (2023). Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet, 401(10371), 105-117.

Højris, I., Overgaard, M., Christensen, J. J., & Overgaard, J. (1999). Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: analysis of DBCG 82b and 82c randomised trials. Radiotherapy Committee of the Danish Breast Cancer Cooperative Group. Lancet, 354(9188), 1425-1430.

IARC (2002). Breast cancer screening Lyon: IARC Press.

Ignatov, A., Eggemann, H., Burger, E., & Ignatov, T. (2018). Patterns of breast cancer relapse in accordance to biological subtype. Journal of Cancer Research and Clinical Oncology, 144(7), 1347-1355.

Im, S. A., Lu, Y. S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., ... Tripathy, D. (2019). Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. New England Journal of Medicine, 381(4), 307-316.

Independent, U. K. P. o. B. C. S. (2012). The benefits and harms of breast cancer screening: an independent review. Lancet, 380(9855), 1778-1786.

Iodice, S., Barile, M., Rotmensz, N., Feroce, I., Bonanni, B., Radice, P., Bernard, L., Maisonneuve, P., & Gandini, S. (2010). Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. European journal of cancer, 46(12), 2275-84.

Iotti, V., Ravaioli, S., Vacondio, R., Coriani, C., Caffarri, S., Sghedoni, R., Nitrosi, A., Ragazzi, M., ... Pattacini, P. (2017). Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging. Breast cancer research, 19(1), 106.

Iwase, T., Saji, S., Iijima, K., Higaki, K., Ohtani, S., Sato, Y., Hozumi, Y., Hasegawa, Y., ... Mukai, H. (2023). Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial. Journal of clinical oncology, 41(18), 3329-3338.

Jacobson, A. (2022). Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer. Oncologist, 27(Suppl 1), S13-s14.

Jagsi, R., Griffith, K. A., Harris, E. E., Wright, J. L., Recht, A., Taghian, A. G., Lee, L., Moran, M. S., ... El-Tamer, M. (2024). Omission of Radiotherapy After Breast-Conserving Surgery for Women With Breast Cancer With Low Clinical and Genomic Risk: 5-Year Outcomes of IDEA. Journal of clinical oncology, 42(4), 390-398.

Jakesz, R., Jonat, W., Gnant, M., Mittlboeck, M., Greil, R., Tausch, C., Hilfrich, J., Kwasny, W., ... Wolfgang, J. (2005). Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet, 366(9484), 455-462.

Jensen, A. K., Kristensen, S. G., Macklon, K. T., Jeppesen, J. V., Fedder, J., Ernst, E., & Andersen, C. Y. (2015). Outcomes of transplantations of cryopreserved ovarian tissue to 41 women in Denmark. Human reproduction, 30(12), 2838-45.

Jereczek-Fossa, B. A., Alterio, D., Jassem, J., Gibelli, B., Tradati, N., & Orecchia, R. (2004). Radiotherapy-induced thyroid disorders. Cancer Treatment Reviews, 30(4), 369-384.

Jochelson, M. S., & Lobbes, M. B. I. (2021). Contrast-enhanced Mammography: State of the Art. Radiology, 299(1), 36-48.

Joensuu, H., Bono, P., Kataja, V., Alanko, T., Kokko, R., Asola, R., Utriainen, T., Turpeenniemi-Hujanen, T., ... Kellokumpu-Lehtinen, P. L. (2009). Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. Journal of clinical oncology, 27(34), 5685-92.

Joensuu, H., Kellokumpu-Lehtinen, P. L., Huovinen, R., Jukkola-Vuorinen, A., Tanner, M., Kokko, R., Ahlgren, J., Auvinen, P., ... Lindman, H. (2012). Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. Journal of clinical oncology, 30(1), 11-8.

Joensuu, H., & Viikari, J. (1986). Thyroid function after postoperative radiation therapy in patients with breast cancer. Acta radiologica. Oncology, 25(3), 167-170.

Joensuu, H., Fraser, J., Wildiers, H., Huovinen, R., Auvinen, P., Utriainen, M., Nyandoto, P., Villman, K. K., ... Lindman, H. (2018). Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial. JAMA oncology, 4(9), 1199-1206.

Joensuu, H., Kellokumpu-Lehtinen, P. L., Bono, P., Alanko, T., Kataja, V., Asola, R., Utriainen, T., Kokko, R., ... Isola, J. (2006). Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. New England Journal of Medicine, 354(8), 809-20.

Johansen, K., Lønning, P. E., Naume, B., Norderhaug, I., Norum, J., Olsen, J. A., Wist, E. (2006). Ny medikamentell behandling av brystkreft - adjuvant behandling med trastuzumab ved tidlig stadium av brystkreft Oslo: Kunnskapssenteret. Hentet fra https://www.fhi.no/publ/eldre/ny-medikamentell-behandling-av-brystkreft.--adjuvant-behandling-med-trastuz/

Johansson, S., Svensson, H., & Denekamp, J. (2002). Dose response and latency for radiation-induced fibrosis, edema, and neuropathy in breast cancer patients. International journal of radiation oncology, biology, physics, 52(5), 1207-19.

Johnson, D. J. (2021). Discussion: MemoryGel Breast Implants: Final Safety and Efficacy Results after 10 Years of Follow-Up. Plastic and reconstructive surgery, 147(3), 567-568.

Johnston, S. R. D., Harbeck, N., Hegg, R., Toi, M., Martin, M., Shao, Z. M., Zhang, Q. Y., Martinez Rodriguez, J. L., ... Rastogi, P. (2020). Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). Journal of clinical oncology, 38(34), 3987-3998.

Johnston, S. R. D., Toi, M., O'Shaughnessy, J., Rastogi, P., Campone, M., Neven, P., Huang, C. S., Huober, J., ... Martin, M. (2023). Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. The Lancet. Oncology, 24(1), 77-90.

Johnston, S., Pippen, J. ,., Pivot, X., Lichinitser, M., Sadeghi, S., Dieras, V., Gomez, H. L., Romieu, G., ... Pegram, M. (2009). Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. Journal of clinical oncology, 27(33), 5538-5546.

Jones, S. E., Savin, M. A., Holmes, F. A., O'Shaughnessy, J. A., Blum, J. L., Vukelja, S., McIntyre, K. J., Pippen, J. E., ... Asmar, L. (2006). Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of clinical oncology, 24(34), 5381-7.

Kaidar-Person, O., Oldenborg, S., & Poortmans, P. (2018). Re-irradiation and Hyperthermia in Breast Cancer. Clinical oncology (Royal College of Radiologists (Great Britain)), 30(2), 73-84.

Kaidar-Person, O., Dahn, H. M., Nichol, A. M., Boersma, L. J., de Ruysscher, D., Meattini, I., Pignol, J. P., Aristei, C., ... Offersen, B. V. (2021). A Delphi study and International Consensus Recommendations: The use of bolus in the setting of postmastectomy radiation therapy for early breast cancer. Radiotherapy and Oncology, 164, 115-121.

Kaidar-Person, O., Vrou Offersen, B., Hol, S., Arenas, M., Aristei, C., Bourgier, C., Cardoso, M. J., Chua, B., ... Poortmans, P. (2019). ESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant-based immediate reconstruction for early stage breast cancer. Radiotherapy and Oncology, 137, 159-166.

Kalinsky, K., Accordino, M. K., Chiuzan, C., Mundi, P. S., Sakach, E., Sathe, C., Ahn, H., Trivedi, M. S., ... Hershman, D. L. (2023). Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial. Journal of clinical oncology, 41(24), 4004-4013.

Kalinsky, K., Bianchini, G., Hamilton, E. P., Graff, S. L., Park, K. H., Jeselsohn, R., Demirci, U., Martin, M., ... Wander, S. A. (2024). Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial. Journal of Clinical Oncology, 42(17 suppl), LBA1001.

Kalinsky, K., Barlow, W. E., Gralow, J. R., Meric-Bernstam, F., Albain, K. S., Hayes, D. F., Lin, N. U., Perez, E. A., ... Hortobagyi, G. N. (2021). 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. New England Journal of Medicine, 385(25), 2336-2347.

Kamby, C., & Sengelov, L. (1997). Pattern of dissemination and survival following isolated locoregional recurrence of breast cancer. A prospective study with more than 10 years of follow up. Breast cancer research and treatment, 45(2), 181-192.

Karlsson, P., Cole, B. F., Colleoni, M., Roncadin, M., Chua, B. H., Murray, E., Price, K. N., Castiglione-Gertsch, M., ... Gruber, G. (2011). Timing of radiotherapy and outcome in patients receiving adjuvant endocrine therapy. International journal of radiation oncology, biology, physics, 80(2), 398-402.

Kaufman, P. A., Awada, A., Twelves, C., Yelle, L., Perez, E. A., Velikova, G., Olivo, M. S., He, Y., ... Cortes, J. (2015). Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. Journal of clinical oncology, 33(6), 594-601.

Kaufman, B., Mackey, J. R., Clemens, M. R., Bapsy, P. P., Vaid, A., Wardley, A., Tjulandin, S., Jahn, M., ... Jones, A. (2009). Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. Journal of clinical oncology, 27(33), 5529-5537.

Kaufmann, M., Karn, T., & Ruckhaberle, E. (2012). Controversies concerning the use of neoadjuvant systemic therapy for primary breast cancer. World journal of surgery, 36(7), 1480-1485.

Kelly, C. M., Juurlink, D. N., Gomes, T., Duong-Hua, M., Pritchard, K. I., Austin, P. C., & Paszat, L. F. (2010). Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ, 340, c693.

Kelly, B. N., Faulkner, H. R., Smith, B. L., Korotkin, J. E., Lanahan, C. R., Brown, C., Gadd, M. A., Specht, M. C., ... Coopey, S. B. (2022). Nipple-Sparing Mastectomy versus Skin-Sparing Mastectomy: Does Saving the Nipple Impact Short- and Long-Term Patient Satisfaction?. Annals of surgical oncology, 29(2), 1033-1040.

Kendall, A., Dowsett, M., Folkerd, E., & Smith, I. (2006). Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Annals of oncology, 17(4), 584-587.

Kenemans, P., Bundred, N. J., Foidart, J. M., Kubista, E., von Schoultz, B., Sismondi, P., Vassilopoulou-Sellin, R., Yip, C. H., ... Beckmann, M. W. (2009). Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. The Lancet. Oncology, 10(2), 135-146.

Kerlikowske, K., Molinaro, A., Cha, I., Ljung, B. M., Ernster, V. L., Stewart, K., Chew, K., Moore, D. H., & Waldman, F. (2003). Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. Journal of the National Cancer Institute, 95(22), 1692-1702.

Khan, Q. J., Bohnenkamp, C., Monson, T., Smith, H. E., Phadnis, M. A., Raja, V., Elia, M., O'Dea, A., ... Sharma, P. (2023). Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial. Journal of clinical oncology, 41(16 suppl), 1007.

Khatcheressian, J. L., Wolff, A. C., Smith, T. J., Grunfeld, E., Muss, H. B., Vogel, V. G., Halberg, F., Somerfield, M. R., & Davidson, N. E. (2006). American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. Journal of clinical oncology, 24(31), 5091-5097.

Kim, T., Giuliano, A. E., & Lyman, G. H. (2006). Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer, 106(1), 4-16.

Kim, S. B., Dent, R., Im, S. A., Espie, M., Blau, S., Tan, A. R., Isakoff, S. J., Oliveira, M., ... investigators, L. (2017). Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. Oncology, 18(10), 1360-1372.

Kisqali. (4. mai 2020). Felleskatalogen [database]. Oslo: Felleskatalogen AS. Hentet 11. mai 2020 fra https://www.felleskatalogen.no/medisin/kisqali-novartis-642779

Klintman, M., Strand, C., Ahlin, C., Beglerbegovic, S., Fjällskog, M. L., Grabau, D., Gudlaugsson, E., Janssen, E. A., ... Ferno, M. (2013). The prognostic value of mitotic activity index (MAI), phosphohistone H3 (PPH3), cyclin B1, cyclin A, and Ki67, alone and in combinations, in node-negative premenopausal breast cancer. PLoS ONE, 8(12), e81902.

Ko, M. J., Park, D. A., Kim, S. H., Ko, E. S., Shin, K. H., Lim, W., Kwak, B. S., & Chang, J. M. (2021). Accuracy of Digital Breast Tomosynthesis for Detecting Breast Cancer in the Diagnostic Setting: A Systematic Review and Meta-Analysis. Korean journal of radiology, 22(8), 1240-1252.

Kollias, J., Murphy, C. A., Elston, C. W., Ellis, I. O., Robertson, J. F., & Blamey, R. W. (1999). The prognosis of small primary breast cancers. European journal of cancer, 35(6), 908-12.

Korde, L. A., Somerfield, M. R., Hershman, D. L., & Neoadjuvant Chemotherapy, ,. E. T. a. T. T. f. B. C. G. E. P. (2022). Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update. Journal of clinical oncology, 40(15), 1696-1698.

Kotsopoulos, J., Gronwald, J., Huzarski, T., Aeilts, A., Randall Armel, S., Karlan, B., Singer, C. F., Eisen, A., ... and the Hereditary Breast Cancer Clinical Study, G. (2023). Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation. Breast cancer research and treatment, 201(2), 257-264.

Koyama, H., Wada, T., Nishizawa, Y., Iwanaga, T., & Aoki, Y. (1977). Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer, 39(4), 1403-9.

Krastev, T. K., Schop, S. J., Hommes, J., Piatkowski, A. A., Heuts, E. M., & van der Hulst, R. (2018). Meta-analysis of the oncological safety of autologous fat transfer after breast cancer. The British journal of surgery, 105(9), 1082-1097.

Krastev, T., van Turnhout, A., Vriens, E., Smits, L., & van der Hulst, R. (2019). Long-term Follow-up of Autologous Fat Transfer vs Conventional Breast Reconstruction and Association With Cancer Relapse in Patients With Breast Cancer. JAMA surgery, 154(1), 56-63.

Kreftregisteret (2018). Årsrapport 2017 med resultater og forbedringstiltak fra Nasjonalt kvalitetsregister for brystkreft. Oslo: Kreftregisteret. Hentet fra https://www.kvalitetsregistre.no/sites/default/files/13_arsrapport_2017_brystkreft.pdf

Krop, I., Ismaila, N., Andre, F., Bast, R. C., Barlow, W., Collyar, D. E., Hammond, M. E., Kuderer, N. M., ... Stearns, V. (2017). Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. Journal of clinical oncology, 35(24), 2838-2847.

Krop, I. E., Kim, S. B., Gonzalez-Martin, A., LoRusso, P. M., Ferrero, J. M., Smitt, M., Yu, R., Leung, A. C., & Wildiers, H. (2014). Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. The Lancet. Oncology, 15(7), 689-99.

Kuchenbaecker, K. B., Hopper, J. L., Barnes, D. R., Phillips, K. A., Mooij, T. M., Roos-Blom, M. J., Jervis, S., van Leeuwen, F. E., ... Olsson, H. (2017). Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA, 317(23), 2402-2416.

Kucuk, O. (2017). Soy foods, isoflavones, and breast cancer. Cancer, 123(11), 1901-1903.

Kuo, S. H., Huang, C. S., Kuo, W. H., Cheng, A. L., Chang, K. J., & Chia-Hsien, C. J. (2008). Comprehensive locoregional treatment and systemic therapy for postmastectomy isolated locoregional recurrence. International journal of radiation oncology, biology, physics, 72(5), 1456-1464.

Kurata, K., Kubo, M., Kai, M., Mori, H., Kawaji, H., Kaneshiro, K., Yamada, M., Nishimura, R., ... Nakamura, M. (2020). Microsatellite instability in Japanese female patients with triple-negative breast cancer. Breast Cancer, 27(3), 490-498.

Kurian, A. W., Sigal, B. M., & Plevritis, S. K. (2010). Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. Journal of clinical oncology, 28(2), 222-31.

Lænkholm, A. V., Jensen, M. B., Eriksen, J. O., Rasmussen, B. B., Knoop, A. S., Buckingham, W., Ferree, S., Schaper, C., ... Ejlertsen, B. (2018). PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer. Journal of clinical oncology, 36(8), 735-740.

Lambertini, M., Ceppi, M., Poggio, F., Peccatori, F. A., Azim, H. A. ,. J., Ugolini, D., Pronzato, P., Loibl, S., ... Del Mastro, L. (2015). Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Annals of oncology, 26(12), 2408-19.

Landercasper, J., Attai, D., Atisha, D., Beitsch, P., Bosserman, L., Boughey, J., Carter, J., Edge, S., ... Cody, H. ,. 3. (2015). Toolbox to Reduce Lumpectomy Reoperations and Improve Cosmetic Outcome in Breast Cancer Patients: The American Society of Breast Surgeons Consensus Conference. Annals of surgical oncology, 22(10), 3174-83.

Larsen, I. K. (2023). Cancer in Norway 2022: Cancer incidence, mortality, survival and prevalence in Norway. Cancer Registry of Norway.

Larsen, I. K. (2021). Cancer in Norway 2020: Cancer incidence, mortality, survival and prevalence in Norway. Cancer Registry of Norway.

Larsen, I. K. (2024). Cancer in Norway 2023: Cancer incidence, mortality, survival and prevalence in Norway. Cancer Registry of Norway.

Larson, K. E., Grobmyer, S. R., & Valente, S. A. (2018). Evaluation of recurrence patterns and survival in modern series of young women with breast cancer. The breast journal, 24(5), 749-754.

Lawenda, B. D., Mondry, T. E., & Johnstone, P. A. (2009). Lymphedema: a primer on the identification and management of a chronic condition in oncologic treatment. CA: a cancer journal for clinicians, 59(1), 8-24.

Lazzeroni, M., Puntoni, M., Guerrieri-Gonzaga, A., Serrano, D., Boni, L., Buttiron Webber, T., Fava, M., Briata, I. M., ... DeCensi, A. (2023). Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study. Journal of clinical oncology, 41(17), 3116-3121.

Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., ... Diaz, L. A. ,. J. (2017). Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science, 357(6349), 409-413.

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., ... Diaz, L. A. ,. J. (2015). PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. New England Journal of Medicine, 372(26), 2509-20.

Lederman, S., Ottery, F. D., Cano, A., Santoro, N., Shapiro, M., Stute, P., Thurston, R. C., English, M., ... Neal-Perry, G. (2023). Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet, 401(10382), 1091-1102.

Lee, L. A., Silverstein, M. J., Chung, C. T., Macdonald, H., Sanghavi, P., Epstein, M., Holmes, D. R., Silberman, H., ... Lagios, M. D. (2006). Breast cancer-specific mortality after invasive local recurrence in patients with ductal carcinoma-in-situ of the breast. American journal of surgery, 192(4), 416-419.

Lee, S. H., Lee, J., Park, J., Park, S. H., Lee, K. E., Lee, S. I., Nam, E., Park, J. O., ... Im, Y. H. (2004). Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Medical oncology, 21(3), 223-231.

Lehman, C. D., Lee, A. Y., & Lee, C. I. (2014). Imaging management of palpable breast abnormalities. AJR. American journal of roentgenology, 203(5), 1142-53.

Leidenius, M. H., Krogerus, L. A., Toivonen, T. S., Leppanen, E. A., & von Smitten, K. A. (2006). The clinical value of parasternal sentinel node biopsy in breast cancer. Annals of surgical oncology, 13(3), 321-326.

Lende, T. H., Janssen, E. A., Gudlaugsson, E., Voorhorst, F., Smaaland, R., van Diest, P., Søiland, H., & Baak, J. P. (2011). In patients younger than age 55 years with lymph node-negative breast cancer, proliferation by mitotic activity index is prognostically superior to adjuvant!. Journal of clinical oncology, 29(7), 852-8.

Leon-Ferre, R. A., Novotny, P. J., Wolfe, E. G., Faubion, S. S., Ruddy, K. J., Flora, D., Dakhil, C. S. R., Rowland, K. M., ... Loprinzi, C. L. (2020). Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603). JNCI cancer spectrum, 4(1), pkz088.

Leon-Ferre, R. A., Jonas, S. F., Salgado, R., Loi, S., de Jong, V., Carter, J. M., Nielsen, T. O., Leung, S., ... Michiels, S. (2024). Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. JAMA, 331(13), 1135-1144.

Levernes, S., Johannessen, D. C. (2003). Volum og doser ved strålebehandling: definisjoner, retningslinjer for bruk, dokumentasjon og rapportering Oslo: Statens strålevern. Hentet fra https://dsa.no/publikasjoner/stralevernrapport-12-2003-volum-og-doser-ved-stralebehandling/straalevernrapport-2003-12-volum-og-doser-ved-straalebehandling-definisjoner-retningslinjer-dokumentasjon-rapportering.pdf

Li, J., Yu, K., Pang, D., Wang, C., Jiang, J., Yang, S., Liu, Y., Fu, P., ... Shao, Z. (2020). Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial. Journal of clinical oncology, 38(16), 1774-1784.

Li, X., You, R., Wang, X., Liu, C., Xu, Z., Zhou, J., Yu, B., Xu, T., ... Zou, Q. (2016). Effectiveness of Prophylactic Surgeries in BRCA1 or BRCA2 Mutation Carriers: A Meta-analysis and Systematic Review. Clinical cancer research, 22(15), 3971-81.

Liang, S., Hallet, J., Simpson, J. S., Tricco, A. C., & Scheer, A. S. (2017). Omission of axillary staging in elderly patients with early stage breast cancer impacts regional control but not survival: A systematic review and meta-analysis. Journal of geriatric oncology, 8(2), 140-147.

Lin, N. U., Murthy, R. K., Abramson, V., Anders, C., Bachelot, T., Bedard, P. L., Borges, V., Cameron, D., ... Winer, E. (2023). Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial. JAMA oncology, 9(2), 197-205.

Lind, P. A., Wennberg, B., Gagliardi, G., & Fornander, T. (2001). Pulmonary complications following different radiotherapy techniques for breast cancer, and the association to irradiated lung volume and dose. Breast cancer research and treatment, 68(3), 199-210.

Litiere, S., Werutsky, G., Fentiman, I. S., Rutgers, E., Christiaens, M. R., Van Limbergen, E., Baaijens, M. H., Bogaerts, J., & Bartelink, H. (2012). Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. The Lancet. Oncology, 13(4), 412-419.

Litton, J. K., Hurvitz, S. A., Mina, L. A., Rugo, H. S., Lee, K. H., Gonçalves, A., Diab, S., Woodward, N., ... Ettl, J. (2020). Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Annals of oncology, 31(11), 1526-1535.

Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K. H., Fehrenbacher, L., Yerushalmi, R., ... Blum, J. L. (2018). Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. New England Journal of Medicine, 379(8), 753-763.

Liu, Y., Malin, J. L., Diamant, A. L., Thind, A., & Maly, R. C. (2013). Adherence to adjuvant hormone therapy in low-income women with breast cancer: the role of provider-patient communication. Breast cancer research and treatment, 137(3), 829-36.

Llombart-Cussac, A., Harper-Wynne, C., Perello, A., Hennequin, A., Fernandez, A., Colleoni, M., Carañana, V., Quiroga, V., ... Cortes, J. (2023). Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial. Journal of clinical oncology, 41(16 suppl), 1001.

Lluch, A., Barrios, C. H., Torrecillas, L., Ruiz-Borrego, M., Bines, J., Segalla, J., Guerrero-Zotano, Á., García-Sáenz, J. A., ... Martín, M. (2020). Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01). Journal of clinical oncology, 38(3), 203-213.

Loesch, D., Asmar, L., McIntyre, K., Doane, L., Monticelli, M., Paul, D., Vukelja, S., Orlando, M., ... O'Shaughnessy, J. A. (2008). Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer. Clinical breast cancer, 8(2), 178-186.

Lohrisch, C., Paltiel, C., Gelmon, K., Speers, C., Taylor, S., Barnett, J., & Olivotto, I. A. (2006). Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer. Journal of clinical oncology, 24(30), 4888-4894.

Loibl, S., Turner, N. C., Ro, J., Cristofanilli, M., Iwata, H., Im, S. A., Masuda, N., Loi, S., ... Dowsett, M. (2017). Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. Oncologist, 22(9), 1028-1038.

Loibl, S., Marmé, F., Martin, M., Untch, M., Bonnefoi, H., Kim, S. B., Bear, H., McCarthy, N., ... von Minckwitz, G. (2021). Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial. Journal of clinical oncology, 39(14), 1518-1530.

Loibl, S., Schneeweiss, A., Huober, J., Braun, M., Rey, J., Blohmer, J. U., Furlanetto, J., Zahm, D. M., ... Untch, M. (2022). Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Annals of oncology, 33(11), 1149-1158.

Loibl, S., Jassem, J., Sonnenblick, A., Parlier, D., Winer, E., Bergh, J., Gelber, R. D., Restuccia, E., ... Piccart, M. (2022). VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up. Annals of oncology, 33(9), 986-987.

Loibl, S., Han, S. N., von Minckwitz, G., Bontenbal, M., Ring, A., Giermek, J., Fehm, T., Van Calsteren, K., ... Amant, F. (2012). Treatment of breast cancer during pregnancy: an observational study. The Lancet. Oncology, 13(9), 887-96.

Loibl, S., O'Shaughnessy, J., Untch, M., Sikov, W. M., Rugo, H. S., McKee, M. D., Huober, J., Golshan, M., ... Geyer, C. E. ,. J. (2018). Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. The Lancet. Oncology, 19(4), 497-509.

Loibl, S., Schmidt, A., Gentilini, O., Kaufman, B., Kuhl, C., Denkert, C., von Minckwitz, G., Parokonnaya, A., ... Amant, F. (2015). Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients. JAMA oncology, 1(8), 1145-53.

Loibl, S., André, F., Bachelot, T., Barrios, C. H., Bergh, J., Burstein, H. J., Cardoso, M. J., Carey, L. A., ... Harbeck, N. (2024). Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of oncology, 35(2), 159-182.

Lopez, M., Papaldo, P., Di Lauro, L., Vici, P., Carpano, S., & Conti, E. M. (1989). 5-Fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer. Oncology, 46(1), 1-5.

Loprinzi, C. L., Kugler, J. W., Barton, D. L., Dueck, A. C., Tschetter, L. K., Nelimark, R. A., Balcueva, E. P., Burger, K. N., ... Jaslowski, A. J. (2007). Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5. Journal of clinical oncology, 25(3), 308-312.

Loprinzi, C. L. (1994). It is now the age to define the appropriate follow-up of primary breast cancer patients. Journal of clinical oncology, 12(5), 881-883.

Lord, S., Ghersi, D., Gattellari, M., Wortley, S., Wilcken, N., & Simes, J. (2004). Antitumour antibiotic containing regimens for metastatic breast cancer. Cochrane database of systematic reviews, (4), CD003367.

Lu, W. L., Jansen, L., Post, W. J., Bonnema, J., Van de Velde, J. C., & De Bock, G. H. (2009). Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis. Breast cancer research and treatment, 114(3), 403-12.

Lu, Y. S., Bin Mohd Mahidin, E. I., Azim, H., Eralp, Y., Yap, Y. S., Im, S. A., Rihani, J., Gokmen, E., ... El Saghir, N. S. (2024). Final results of RIGHT Choice: Ribociclib plus endocrine therapy vs combination chemotherapy in premenopausal women with clinically aggressive HR+/HER2- advanced breast cancer. Journal of clinical oncology, , Jco2400144.

Luck, H. J., & Roche, H. (2002). Weekly paclitaxel: an effective and well-tolerated treatment in patients with advanced breast cancer. Critical Reviews in Oncology/Hematology, 44(Suppl), S15-S30.

Ludwig, K. K., Neuner, J., Butler, A., Geurts, J. L., & Kong, A. L. (2016). Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. American journal of surgery, 212(4), 660-669.

Lyman, G. H., Giuliano, A. E., Somerfield, M. R., Benson, A. B. ,., Bodurka, D. C., Burstein, H. J., Cochran, A. J., Cody, H. S. ,., ... Winer, E. P. (2005). American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. Journal of clinical oncology, 23(30), 7703-7720.

Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., ... van der Pal, H. J. H. (2022). 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European heart journal, 43(41), 4229-4361.

Lønning, P. E., Taylor, P. D., Anker, G., Iddon, J., Wie, L., Jørgensen, L. M., Mella, O., & Howell, A. (2001). High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast cancer research and treatment, 67(2), 111-116.

Lønning, P. E., & Eikesdal, H. P. (2013). Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. Endocrine-related cancer, 20(4), R183-201.

MacDonald, H. R., Silverstein, M. J., Mabry, H., Moorthy, B., Ye, W., Epstein, M. S., Holmes, D., Silberman, H., & Lagios, M. (2005). Local control in ductal carcinoma in situ treated by excision alone: incremental benefit of larger margins. American journal of surgery, 190(4), 521-525.

Madorsky-Feldman, D., Sklair-Levy, M., Perri, T., Laitman, Y., Paluch-Shimon, S., Schmutzler, R., Rhiem, K., Lester, J., ... Friedman, E. (2016). An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. Breast cancer research and treatment, 157(2), 319-327.

Madsen, S. (2009). Planteøstrogener og overgangsplager hos kvinner. Tidsskrift for den norske legeforening, 129(21), 2238-2239.

Major, P., Lortholary, A., Hon, J., Abdi, E., Mills, G., Menssen, H. D., Yunus, F., Bell, R., ... Seaman, J. (2001). Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. Journal of clinical oncology, 19(2), 558-567.

Mamounas, E. P., Bandos, H., Lembersky, B. C., Jeong, J. H., Geyer, C. E., Rastogi, P., Fehrenbacher, L., Graham, M. L., ... Wolmark, N. (2020). Abstract GS4-01: Ten-year results from NRG Oncology/NSABP B-42: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor+ breast cancer (BC) who have completed previous adjuvant therapy with an aromatase inhibitor (AI). Cancer Research, 80(4 Suppl), GS4-01.

Mamounas, E. P., Bandos, H., Lembersky, B. C., Jeong, J. H., Geyer, C. E. ,. J., Rastogi, P., Fehrenbacher, L., Graham, M. L., ... Wolmark, N. (2019). Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, 20(1), 88-99.

Mann, R. M., Loo, C. E., Wobbes, T., Bult, P., Barentsz, J. O., Gilhuijs, K. G., & Boetes, C. (2010). The impact of preoperative breast MRI on the re-excision rate in invasive lobular carcinoma of the breast. Breast cancer research and treatment, 119(2), 415-22.

Mann, R. M., Balleyguier, C., Baltzer, P. A., Bick, U., Colin, C., Cornford, E., Evans, A., Fallenberg, E., ... Sardanelli, F. (2015). Breast MRI: EUSOBI recommendations for women's information. European radiology, 25(12), 3669-78.

Mann, R. M., Kuhl, C. K., Kinkel, K., & Boetes, C. (2008). Breast MRI: guidelines from the European Society of Breast Imaging. European radiology, 18(7), 1307-1318.

Mannu, G. S., Wang, Z., Broggio, J., Charman, J., Cheung, S., Kearins, O., Dodwell, D., & Darby, S. C. (2020). Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988-2014: population based observational cohort study. BMJ, 369, m1570.

Mansell, J., Weiler-Mithoff, E., Stallard, S., Doughty, J. C., Mallon, E., & Romics, L. (2017). Oncoplastic breast conservation surgery is oncologically safe when compared to wide local excision and mastectomy. Breast, 32, 179-185.

Manson, J. E., Aragaki, A. K., Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Chlebowski, R. T., Howard, B. V., ... Wactawski-Wende, J. (2017). Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. JAMA, 318(10), 927-938.

Marinovich, M. L., Sardanelli, F., Ciatto, S., Mamounas, E., Brennan, M., Macaskill, P., Irwig, L., von Minckwitz, G., & Houssami, N. (2012). Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI. Breast, 21(5), 669-77.

Marinovich, M. L., Macaskill, P., Irwig, L., Sardanelli, F., von Minckwitz, G., Mamounas, E., Brennan, M., Ciatto, S., & Houssami, N. (2013). Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy. British Journal of Cancer, 109(6), 1528-36.

Marinovich, M. L., Houssami, N., Macaskill, P., Sardanelli, F., Irwig, L., Mamounas, E. P., von Minckwitz, G., Brennan, M. E., & Ciatto, S. (2013). Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. Journal of the National Cancer Institute, 105(5), 321-33.

Marmolejo, D. H., Wong, M. Y. Z., Bajalica-Lagercrantz, S., Tischkowitz, M., Balmana, J., & extended, E. R. N. G. T. G. (2021). Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe. European journal of human genetics : EJHG, 64(12), 104350.

Martaindale, S., Omofoye, T. S., Teichgraeber, D. C., Hess, K. R., & Whitman, G. J. (2020). Imaging Follow-up Versus Surgical Excision for Radial Scars Identified on Tomosynthesis-Guided Core Needle Biopsy. Academic Radiology, 27(3), 389-394.

Martelli, G., Boracchi, P., Ardoino, I., Lozza, L., Bohm, S., Vetrella, G., & Agresti, R. (2012). Axillary dissection versus no axillary dissection in older patients with T1N0 breast cancer: 15-year results of a randomized controlled trial. Annals of surgery, 256(6), 920-4.

Martin, M., Holmes, F. A., Ejlertsen, B., Delaloge, S., Moy, B., Iwata, H., von Minckwitz, G., Chia, S. K. L., ... Chan, A. (2017). Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, 18(12), 1688-1700.

Martin, M., Pienkowski, T., Mackey, J., Pawlicki, M., Guastalla, J. P., Weaver, C., Tomiak, E., Al-Tweigeri, T., ... Vogel, C. (2005). Adjuvant docetaxel for node-positive breast cancer. New England Journal of Medicine, 352(22), 2302-2313.

Martín, M., Ruiz Simón, A., Ruiz Borrego, M., Ribelles, N., Rodríguez-Lescure, Á., Muñoz-Mateu, M., González, S., Margelí Vila, M., ... Lluch, A. (2015). Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study. Journal of clinical oncology, 33(32), 3788-95.

Marty, M., Cognetti, F., Maraninchi, D., Snyder, R., Mauriac, L., Tubiana-Hulin, M., Chan, S., Grimes, D., ... Extra, J. M. (2005). Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. Journal of clinical oncology, 23(19), 4265-4274.

Masannat, Y. A., Bains, S. K., Pinder, S. E., & Purushotham, A. D. (2013). Challenges in the management of pleomorphic lobular carcinoma in situ of the breast. Breast, 22(2), 194-196.

Masuda, N., Lee, S. J., Ohtani, S., Im, Y. H., Lee, E. S., Yokota, I., Kuroi, K., Im, S. A., ... Toi, M. (2017). Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. New England Journal of Medicine, 376(22), 2147-2159.

Mateo, J., Porta, N., Bianchini, D., McGovern, U., Elliott, T., Jones, R., Syndikus, I., Ralph, C., ... de Bono, J. S. (2020). Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. The Lancet. Oncology, 21(1), 162-174.

Mayer, I. A., Zhao, F., Arteaga, C. L., Symmans, W. F., Park, B. H., Burnette, B. L., Tevaarwerk, A. J., Garcia, S. F., ... Miller, K. D. (2021). Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. Journal of clinical oncology, 39(23), 2539-2551.

Mayer, E. L., Ren, Y., Wagle, N., Mahtani, R., Ma, C., DeMichele, A., Cristofanilli, M., Meisel, J., ... Tolaney, S. (2023). Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer. Cancer Research, 83(5 Suppl), GS3-06.

McCormack, P. M., Bains, M. S., Burt, M. E., Martini, N., Chaglassian, T., & Hidalgo, D. A. (1989). Local recurrent mammary carcinoma failing multimodality therapy. A solution. Archives of surgery, 124(2), 158-161.

McCulley, S. J., Schaverien, M. V., Tan, V. K., & Macmillan, R. D. (2015). Lateral thoracic artery perforator (LTAP) flap in partial breast reconstruction. Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 68(5), 686-91.

McGale, P., Taylor, C., Correa, C., Cutter, D., Duane, F., Ewertz, M., Gray, R., Mannu, G., ... Darby, S. (2014). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet, 383(9935), 2127-35.

McGuire, S. E., Gonzalez-Angulo, A. M., Huang, E. H., Tucker, S. L., Kau, S. W., Yu, T. K., Strom, E. A., Oh, J. L., ... Buchholz, T. A. (2007). Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. International journal of radiation oncology, biology, physics, 68(4), 1004-1009.

McNeely, M. L., Magee, D. J., Lees, A. W., Bagnall, K. M., Haykowsky, M., & Hanson, J. (2004). The addition of manual lymph drainage to compression therapy for breast cancer related lymphedema: a randomized controlled trial. Breast cancer research and treatment, 86(2), 95-106.

McNeely, M. L., Campbell, K., Ospina, M., Rowe, B. H., Dabbs, K., Klassen, T. P., Mackey, J., & Courneya, K. (2010). Exercise interventions for upper-limb dysfunction due to breast cancer treatment. Cochrane database of systematic reviews, (6), CD005211.

Meattini, I., Marrazzo, L., Saieva, C., Desideri, I., Scotti, V., Simontacchi, G., Bonomo, P., Greto, D., ... Livi, L. (2020). Accelerated Partial-Breast Irradiation Compared With Whole-Breast Irradiation for Early Breast Cancer: Long-Term Results of the Randomized Phase III APBI-IMRT-Florence Trial. Journal of clinical oncology, 38(35), 4175-4183.

Meattini, I., Becherini, C., Boersma, L., Kaidar-Person, O., Marta, G. N., Montero, A., Offersen, B. V., Aznar, M. C., ... Coles, C. E. (2022). European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. The Lancet. Oncology, 23(1), e21-e31.

Meattini, I., Becherini, C., Caini, S., Coles, C. E., Cortes, J., Curigliano, G., de Azambuja, E., Isacke, C. M., ... Consensus Panellist Group (2024). International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations. The Lancet. Oncology, 25(2), e73-e83.

Mehta, R. S., Barlow, W. E., Albain, K. S., Vandenberg, T. A., Dakhil, S. R., Tirumali, N. R., Lew, D. L., Hayes, D. F., ... Hortobagyi, G. N. (2019). Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. New England Journal of Medicine, 380(13), 1226-1234.

Mendenhall, N. P., Devine, J. W., Mendenhall, W. M., Bland, K. I., Million, R. R., & Copeland, E. M. ,. (1988). Isolated local-regional recurrence following mastectomy for adenocarcinoma of the breast treated with radiation therapy alone or combined with surgery and/or chemotherapy. Radiotherapy and Oncology, 12(3), 177-185.

Menes, T. S., Tartter, P. I., Bleiweiss, I., Godbold, J. H., Estabrook, A., & Smith, S. R. (2005). The consequence of multiple re-excisions to obtain clear lumpectomy margins in breast cancer patients. Annals of surgical oncology, 12(11), 881-885.

Metcalfe, K., Gershman, S., Ghadirian, P., Lynch, H. T., Snyder, C., Tung, N., Kim-Sing, C., Eisen, A., ... Narod, S. A. (2014). Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ, 348, g226.

Metcalfe, K., Lynch, H. T., Ghadirian, P., Tung, N., Olivotto, I., Warner, E., Olopade, O. I., Eisen, A., ... Narod, S. A. (2004). Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Journal of clinical oncology, 22(12), 2328-35.

Metcalfe, K., Lynch, H. T., Foulkes, W. D., Tung, N., Kim-Sing, C., Olopade, O. I., Eisen, A., Rosen, B., ... Narod, S. A. (2015). Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. JAMA oncology, 1(3), 306-13.

Michell, M. J., & Batohi, B. (2018). Role of tomosynthesis in breast imaging going forward. Clinical radiology, 73(4), 358-371.

Mieog, J. S., van der Hage, J. A., & van de Velde, C. J. (2007). Neoadjuvant chemotherapy for operable breast cancer. The British journal of surgery, 94(10), 1189-200.

Miles, D. W., Gligorov, J., Andre, F., Cameron, D., Schneeweiss, A., Barrios, C. H., Xu, B., Wardley, A. M., ... O'Shaughnessy, J. (2020). Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) +/- atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC). Annals of oncology, 31(Suppl 4), S1147-S1148.

Mittendorf, E. A., Jeruss, J. S., Tucker, S. L., Kolli, A., Newman, L. A., Gonzalez-Angulo, A. M., Buchholz, T. A., Sahin, A. A., ... Hunt, K. K. (2011). Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. Journal of clinical oncology, 29(15), 1956-62.

Mittendorf, E. A., Zhang, H., Barrios, C. H., Saji, S., Jung, K. H., Hegg, R., Koehler, A., Sohn, J., ... Harbeck, N. (2020). Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet, 396(10257), 1090-1100.

Möbus, V., Diel, I. J., Elling, D., Harbeck, N., Jackisch, C., Thomssen, C., ... Untch, M. (2011). GAIN Study: A Phase III Trial To Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients with Node-Positive Primary Breast Cancer – 1st Interim Efficacy Analysis. San Antonio: Cancer Therapy & Research Center at UT Health Science Center. Hentet fra http://cancerres.aacrjournals.org/content/71/24_Supplement/S2-4

Modi, S., Jacot, W., Yamashita, T., Sohn, J., Vidal, M., Tokunaga, E., Tsurutani, J., Ueno, N. T., ... Cameron, D. A. (2022). Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. New England Journal of Medicine, 387(1), 9-20.

Modi, S., Saura, C., Yamashita, T., Park, Y. H., Kim, S. B., Tamura, K., Andre, F., Iwata, H., ... Krop, I. (2020). Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. New England Journal of Medicine, 382(7), 610-621.

Moinfar, F., Man, Y. G., Bratthauer, G. L., Ratschek, M., & Tavassoli, F. A. (2000). Genetic abnormalities in mammary ductal intraepithelial neoplasia-flat type ("clinging ductal carcinoma in situ"): a simulator of normal mammary epithelium. Cancer, 88(9), 2072-2081.

Mokbel, K., & Cutuli, B. (2006). Heterogeneity of ductal carcinoma in situ and its effects on management. The Lancet. Oncology, 7(9), 756-765.

Molina-Montes, E., Perez-Nevot, B., Pollan, M., Sanchez-Cantalejo, E., Espin, J., & Sanchez, M. J. (2014). Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis. Breast, 23(6), 721-42.

Montgomery, D. A., Krupa, K., & Cooke, T. G. (2007). Follow-up in breast cancer: does routine clinical examination improve outcome? A systematic review of the literature. British Journal of Cancer, 97(12), 1632-41.

Moore, K. N., Secord, A. A., Geller, M. A., Miller, D. S., Cloven, N., Fleming, G. F., Wahner Hendrickson, A. E., Azodi, M., ... Monk, B. J. (2019). Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. The Lancet. Oncology, 20(5), 636-648.

Moore, H. C. F., Unger, J. M., Phillips, K., Boyle, F., Hitre, E., Porter, D., Francis, P. A., Goldstein, L. J., ... Albain, K. S. (2015). Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy. New England Journal of Medicine, 372(10), 923-932.

Moorman, P. G., Havrilesky, L. J., Gierisch, J. M., Coeytaux, R. R., Lowery, W. J., Peragallo Urrutia, R., Dinan, M., McBroom, A. J., ... Myers, E. R. (2013). Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. Journal of clinical oncology, 31(33), 4188-98.

Moran, M. S., Schnitt, S. J., Giuliano, A. E., Harris, J. R., Khan, S. A., Horton, J., Klimberg, S., Chavez-MacGregor, M., ... Morrow, M. (2014). Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Annals of surgical oncology, 21(3), 704-16.

Morante, Z., Ruiz, R., Araujo, J. M., Pinto, J. A., Cruz-Ku, G., Urrunaga-Pastor, D., Namuche, F., Flores, C., ... Gómez, H. L. (2021). Impact of the Delayed Initiation of Adjuvant Chemotherapy in the Outcome of Triple Negative Breast Cancer. Clinical breast cancer, 21(3), 239-246.e4.

Moravek, M. B., Confino, R., Smith, K. N., Kazer, R. R., Klock, S. C., Lawson, A. K., Gradishar, W. J., & Pavone, M. E. (2018). Long-term outcomes in cancer patients who did or did not pursue fertility preservation. Fertility and Sterility, 109(2), 349-355.

Morra, A., Mavaddat, N., Muranen, T. A., Ahearn, T. U., Allen, J., Andrulis, I. L., Auvinen, P., Becher, H., ... Schmidt, M. K. (2023). The impact of coding germline variants on contralateral breast cancer risk and survival. American journal of human genetics, 110(3), 475-486.

Morrow, M., Van Zee, K. J., Solin, L. J., Houssami, N., Chavez-MacGregor, M., Harris, J. R., Horton, J., Hwang, S., ... Moran, M. S. (2016). Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ. Journal of clinical oncology, 34(33), 4040-4046.

Morrow, M., Schnitt, S. J., & Norton, L. (2015). Current management of lesions associated with an increased risk of breast cancer. Nature reviews. Clinical oncology, 12(4), 227-38.

Moschetti, I., Cinquini, M., Lambertini, M., Levaggi, A., & Liberati, A. (2016). Follow-up strategies for women treated for early breast cancer. Cochrane database of systematic reviews, 2016(5), CD001768.

Mouridsen, H., Giobbie-Hurder, A., Goldhirsch, A., Thurlimann, B., Paridaens, R., Smith, I., Mauriac, L., Forbes, J. F., ... Coates, A. S. (2009). Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. New England Journal of Medicine, 361(8), 766-776.

Moy, B., Rumble, R. B., & Carey, L. A. (2022). Chemotherapy and Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Rapid Recommendation Update. Journal of clinical oncology, 40(26), 3088-3090.

Mulder, R. L., Hudson, M. M., Bhatia, S., Landier, W., Levitt, G., Constine, L. S., Wallace, W. H., van Leeuwen, F. E., ... Oeffinger, K. C. (2020). Updated Breast Cancer Surveillance Recommendations for Female Survivors of Childhood, Adolescent, and Young Adult Cancer From the International Guideline Harmonization Group. Journal of clinical oncology, 38(35), 4194-4207.

Murphy, C., Anderson, P. R., Li, T., Bleicher, R. J., Sigurdson, E. R., Goldstein, L. J., Swaby, R., Denlinger, C., ... Freedman, G. M. (2011). Impact of the radiation boost on outcomes after breast-conserving surgery and radiation. International journal of radiation oncology, biology, physics, 81(1), 69-76.

Murray Brunt, A., Haviland, J. S., Wheatley, D. A., Sydenham, M. A., Alhasso, A., Bloomfield, D. J., Chan, C., Churn, M., ... Yarnold, J. R. (2020). Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet, 395(10237), 1613-1626.

Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Lin, N. U., Borges, V., ... Winer, E. P. (2020). Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine, 382(7), 597-609.

Muscolino, G., Valente, M., Lequaglie, C., & Ravasi, G. (1992). Correlation between first disease-free interval from mastectomy to second disease-free interval from chest wall resection. European journal of surgical oncology, 18(1), 49-52.

Musolino, A., Campone, M., Neven, P., Denduluri, N., Barrios, C. H., Cortes, J., Blackwell, K., Soliman, H., ... Andre, F. (2017). Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy. Breast cancer research, 19(1), 18.

Muss, H. B., Biganzoli, L., Sargent, D. J., & Aapro, M. (2007). Adjuvant therapy in the elderly: making the right decision. Journal of clinical oncology, 25(14), 1870-1875.

Muss, H. B., Tu, D., Ingle, J. N., Martino, S., Robert, N. J., Pater, J. L., Whelan, T. J., Palmer, M. J., ... Goss, P. E. (2008). Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. Journal of clinical oncology, 26(12), 1956-1964.

Møller, P., Stormorken, A., Holmen, M. M., Hagen, A. I., Vabø, A., & Mæhle, L. (2014). The clinical utility of genetic testing in breast cancer kindreds: a prospective study in families without a demonstrable BRCA mutation. Breast cancer research and treatment, 144(3), 607-14.

Nabholtz, J. M., Senn, H. J., Bezwoda, W. R., Melnychuk, D., Deschenes, L., Douma, J., Vandenberg, T. A., Rapoport, B., ... Aapro, M. (1999). Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. Journal of clinical oncology, 17(5), 1413-1424.

Nagaraja, V., Edirimanne, S., & Eslick, G. D. (2016). Is Sentinel Lymph Node Biopsy Necessary in Patients Undergoing Prophylactic Mastectomy? A Systematic Review and Meta-Analysis. The breast journal, 22(2), 158-65.

Nasjonalt kvalitetsregister for brystkreft (2023). Årsrapport 2022: Resultater og forbedringstiltak fra Nasjonalt kvalitetsregister for brystkreft Oslo: Kreftregisteret. Hentet fra https://www.kreftregisteret.no/globalassets/publikasjoner-og-rapporter/arsrapporter/publisert-2023/arsrapport-2022-nasjonalt-kvalitetsregister-for-brystkreft.pdf

Natori, A., Ethier, J. L., Amir, E., & Cescon, D. W. (2017). Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials. European journal of cancer, 77, 40-47.

Nayar, U., Cohen, O., Kapstad, C., Cuoco, M. S., Waks, A. G., Wander, S. A., Painter, C., Freeman, S., ... Wagle, N. (2018). Acquired HER2 mutations in ER(+) metastatic breast cancer confer resistance to estrogen receptor-directed therapies. Nature genetics, 51(2), 207-216.

Nelson, H. D., Vesco, K. K., Haney, E., Fu, R., Nedrow, A., Miller, J., Nicolaidis, C., Walker, M., & Humphrey, L. (2006). Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA, 295(17), 2057-2071.

Nelson, J. A., Allen, R. J. ,. J., Polanco, T., Shamsunder, M., Patel, A. R., McCarthy, C. M., Matros, E., Dayan, J. H., ... Pusic, A. L. (2019). Long-term Patient-reported Outcomes Following Postmastectomy Breast Reconstruction: An 8-year Examination of 3268 Patients. Annals of surgery, 270(3), 473-483.

Nichol, A., Narinesingh, D., Raman, S., Germain, F., Chan, E. K., Tran, E., Gondara, L., Speers, C., ... Truong, P. (2021). The Effect of Bolus on Local Control for Patients Treated With Mastectomy and Radiation Therapy. International journal of radiation oncology, biology, physics, 110(5), 1360-1369.

Nichols, H. B., Berrington de González, A., Lacey, J. V. ,. J., Rosenberg, P. S., & Anderson, W. F. (2011). Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. Journal of clinical oncology, 29(12), 1564-9.

Nielsen, T. O., Parker, J. S., Leung, S., Voduc, D., Ebbert, M., Vickery, T., Davies, S. R., Snider, J., ... Ellis, M. J. (2010). A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clinical cancer research, 16(21), 5222-32.

Nielsen, T. O., Leung, S. C. Y., Rimm, D. L., Dodson, A., Acs, B., Badve, S., Denkert, C., Ellis, M. J., ... Hayes, D. F. (2021). Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. Journal of the National Cancer Institute, 113(7), 808-819.

Nielsen, A. W. M., Thorsen, L. B. J., Overgaard, J., Özcan, D., Matthiessen, L. W., Maae, E., Milo, M. L. H., Nielsen, M. H., ... Offersen, B. V. (2024). DBCG IMN2: Internal mammary node irradiation in 4541 high-risk breast cancer patients treated 2007-2014. Radiotherapy and Oncology, 194(Suppl 1), s728-s731.

Nieweg, O. E., & Bartelink, H. (2004). Implications of lymphatic mapping for staging and adjuvant treatment of patients with breast cancer. European journal of cancer, 40(2), 179-181.

Nilsson, C., & Valachis, A. (2015). The role of boost and hypofractionation as adjuvant radiotherapy in patients with DCIS: a meta-analysis of observational studies. Radiotherapy and Oncology, 114(1), 50-5.

Nitz, U., Gluz, O., Clemens, M., Malter, W., Reimer, T., Nuding, B., Aktas, B., Stefek, A., ... Harbeck, N. (2019). West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. Journal of clinical oncology, 37(10), 799-808.

Njor, S., Nystrom, L., Moss, S., Paci, E., Broeders, M., Segnan, N., & Lynge, E. (2012). Breast cancer mortality in mammographic screening in Europe: a review of incidence-based mortality studies. Journal of medical screening, 19 Suppl 1, 33-41.

Norsk bryst cancer gruppe (2022). Algoritme for kontroll av LVEF under anti-HER2 behandling og kontinuering/diskontinuering av behandlingen Oslo: NBCG. Hentet fra https://nbcg.no/behandlingsskjemaer/medikamentell-behandling/

Norsk bryst cancer gruppe (2022). Veiledende oversikt for endokrin behandling av potensielt endokrin sensitiv HR+HER2 metastatisk brystkreft* Oslo: NBCG. Hentet fra https://nbcg.no/behandlingsskjemaer/medikamentell-behandling/

Norsk bryst cancer gruppe (2024). Retningslinjer for cyteostatisk behandling av metastatisk/avansert brystkreft* Oslo: NBCG. Hentet fra https://nbcg.no/behandlingsskjemaer/medikamentell-behandling/

Nystrom, L., Andersson, I., Bjurstam, N., Frisell, J., Nordenskjold, B., & Rutqvist, L. E. (2002). Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet, 359(9310), 909-919.

O'Brien, M. E., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., ... Tendler, C. (2004). Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Annals of oncology, 15(3), 440-449.

O'Shaughnessy, J., Petrakova, K., Sonke, G. S., Conte, P., Arteaga, C. L., Cameron, D. A., Hart, L. L., Villanueva, C., ... Hortobagyi, G. N. (2018). Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial. Breast cancer research and treatment, 168(1), 127-134.

O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C. (2011). Iniparib plus chemotherapy in metastatic triple-negative breast cancer. New England Journal of Medicine, 364(3), 205-214.

Offersen, B., Nielsen, H. M., Jacobsen, E. H., Nielsen, M. H., Krause, M., Stenbygaard, L., Mjaaland, I., Schreiber, A., ... Overgaard, J. (2018). OC-0596: Hypo- vs normofractionated radiation of early breast cancer in the randomized DBCG HYPO trial. Radiotherapy and Oncology, 127(Suppl 1), S312.

Offersen, B. V., Alsner, J., Nielsen, H. M., Jakobsen, E. H., Nielsen, M. H., Krause, M., Stenbygaard, L., Mjaaland, I., ... Overgaard, J. (2020). Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial. Journal of clinical oncology, 38(31), 3615-3625.

Offersen, B. V., Boersma, L. J., Kirkove, C., Hol, S., Aznar, M. C., Biete Sola, A., Kirova, Y. M., Pignol, J. P., ... Poortmans, P. (2015). ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer. Radiotherapy and Oncology, 114(1), 3-10.

Offersen, B. V., Boersma, L. J., Kirkove, C., Hol, S., Aznar, M. C., Sola, A. B., Kirova, Y. M., Pignol, J. P., ... Poortmans, P. (2016). ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, version 1.1. Radiotherapy and Oncology, 118(1), 205-8.

Offersen, B. V., Overgaard, M., Kroman, N., & Overgaard, J. (2009). Accelerated partial breast irradiation as part of breast conserving therapy of early breast carcinoma: a systematic review. Radiotherapy and Oncology, 90(1), 1-13.

Ohnstad, H. O., Borgen, E., Falk, R. S., Lien, T. G., Aaserud, M., Sveli, M. A. T., Kyte, J. A., Kristensen, V. N., ... Naume, B. (2017). Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up. Breast cancer research, 19(1), 120.

Ohnstad, H. O., Blix, E. S., Akslen, L. A., Gilje, B., Raj, S. X., Skjerven, H., Borgen, E., Janssen, E. A. M., ... Naume, B. (2024). Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer-a prospective national multicentre study (EMIT-1). ESMO open, 9(6), 103475.

Olinger, T. A., Berlin, N. L., Qi, J., Hamill, J. B., Kim, H. M., Pusic, A. L., Wilkins, E. G., & Momoh, A. O. (2020). Outcomes of Immediate Implant-Based Mastectomy Reconstruction in Women with Previous Breast Radiotherapy. Plastic and reconstructive surgery, 145(6), 1029e-1036e.

Oliveira, D., Fernandes, S., Miguel, I., Fragoso, S., & Vaz, F. (2023). Is There a Role for Risk-Reducing Bilateral Breast Surgery in BRCA1/2 Ovarian Cancer Survivors? An Observational Study. Current oncology, 30(9), 7810-7817.

Olivotto, I. A., Lesperance, M. L., Truong, P. T., Nichol, A., Berrang, T., Tyldesley, S., Germain, F., Speers, C., ... Kennecke, H. (2009). Intervals longer than 20 weeks from breast-conserving surgery to radiation therapy are associated with inferior outcome for women with early-stage breast cancer who are not receiving chemotherapy. Journal of clinical oncology, 27(1), 16-23.

Orecchia, R., Veronesi, U., Maisonneuve, P., Galimberti, V. E., Lazzari, R., Veronesi, P., Jereczek-Fossa, B. A., Cattani, F., ... Intra, M. (2021). Intraoperative irradiation for early breast cancer (ELIOT): long-term recurrence and survival outcomes from a single-centre, randomised, phase 3 equivalence trial. The Lancet. Oncology, 22(5), 597-608.

Osswald, R., Boss, A., Lindenblatt, N., Vorburger, D., & Dedes, K. (2020). Does lipofilling after oncologic breast surgery increase the amount of suspicious imaging and required biopsies?-A systematic meta-analysis. The breast journal, 26(5), 847-859.

Ottesen, G. L., Graversen, H. P., Blichert-Toft, M., Christensen, I. J., & Andersen, J. A. (2000). Carcinoma in situ of the female breast. 10 year follow-up results of a prospective nationwide study. Breast cancer research and treatment, 62(3), 197-210.

Overgaard, M., Jensen, M. B., Overgaard, J., Hansen, P. S., Rose, C., Andersson, M., Kamby, C., Kjaer, M., ... Mouridsen, H. T. (1999). Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet, 353(9165), 1641-1648.

Overgaard, M., Hansen, P. S., Overgaard, J., Rose, C., Andersson, M., Bach, F., Kjaer, M., Gadeberg, C. C., ... Zedeler, K. (1997). Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. New England Journal of Medicine, 337(14), 949-955.

Pagani, O., Francis, P. A., Fleming, G. F., Walley, B. A., Viale, G., Colleoni, M., Láng, I., Gómez, H. L., ... Regan, M. M. (2020). Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. Journal of clinical oncology, 38(12), 1293-1303.

Pagani, O., Walley, B. A., Fleming, G. F., Colleoni, M., Láng, I., Gomez, H. L., Tondini, C., Burstein, H. J., ... Francis, P. A. (2023). Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. Journal of clinical oncology, 41(7), 1376-1382.

Pagani, O., Regan, M. M., Walley, B. A., Fleming, G. F., Colleoni, M., Lang, I., Gomez, H. L., Tondini, C., ... Francis, P. A. (2014). Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. New England Journal of Medicine, 371(2), 107-18.

Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., Cronin, M., Baehner, F. L., ... Wolmark, N. (2006). Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. Journal of clinical oncology, 24(23), 3726-34.

Palli, D., Russo, A., Saieva, C., Ciatto, S., Rosselli Del, T. M., Distante, V., & Pacini, P. (1999). Intensive vs clinical follow-up after treatment of primary breast cancer: 10-year update of a randomized trial. National Research Council Project on Breast Cancer Follow-up. JAMA, 281(17), 1586.

Pan, H., Gray, R., Braybrooke, J., Davies, C., Taylor, C., McGale, P., Peto, R., Pritchard, K. I., ... Hayes, D. F. (2017). 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. New England Journal of Medicine, 377(19), 1836-1846.

Panayi, A. C., Foroutanjazi, S., Parikh, N., Haug, V., Kauke-Navarro, M., Diehm, Y. F., & Pomahac, B. (2022). The modified 5-item frailty index is a predictor of perioperative risk in breast reconstruction: An analysis of 40,415 cases. Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 75(9), 2941-2954.

Pandya, K. J., Raubertas, R. F., Flynn, P. J., Hynes, H. E., Rosenbluth, R. J., Kirshner, J. J., Pierce, H. I., Dragalin, V., & Morrow, G. R. (2000). Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Annals of internal medicine, 132(10), 788-793.

Papaldo, P., Fabi, A., Ferretti, G., Mottolese, M., Cianciulli, A. M., Di, C. B., Pino, M. S., Carlini, P., ... Cognetti, F. (2006). A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. Annals of oncology, 17(4), 630-636.

Parazzini, F., Colli, E., Scatigna, M., & Tozzi, L. (1993). Treatment with tamoxifen and progestins for metastatic breast cancer in postmenopausal women: a quantitative review of published randomized clinical trials. Oncology, 50(6), 483-489.

Park, Y. H., Kim, T. Y., Kim, G. M., Kang, S. Y., Park, I. H., Kim, J. H., Lee, K. E., Ahn, H. K., ... Im, S. A. (2019). Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. The Lancet. Oncology, 20(12), 1750-1759.

Partridge, A. H., Rumble, R. B., Carey, L. A., Come, S. E., Davidson, N. E., Di Leo, A., Gralow, J., Hortobagyi, G. N., ... Smith, I. E. (2014). Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of clinical oncology, 32(29), 3307-29.

Partridge, A. H., Wang, P. S., Winer, E. P., & Avorn, J. (2003). Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. Journal of clinical oncology, 21(4), 602-6.

Partridge, A. H., Niman, S. M., Ruggeri, M., Peccatori, F. A., Azim, H. A. ,. J., Colleoni, M., Saura, C., Shimizu, C., ... Pagani, O. (2023). Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer. The New England journal of medicine, 388(18), 1645-1656.

Patel, B. K., Davis, J., Ferraro, C., Kosiorek, H., Hasselbach, K., Ocal, T., & Pockaj, B. (2018). Value Added of Preoperative Contrast-Enhanced Digital Mammography in Patients With Invasive Lobular Carcinoma of the Breast. Clinical breast cancer, 18(6), e1339-e1345.

Paterson, A. H. G., Anderson, S. J., Lembersky, B. C., Fehrenbacher, L., Falkson, C. I., King, K. M., ... Weir, L. M. (2011). NSABP Protocol B-34: A Clinical Trial Comparing Adjuvant Clodronate vs. Placebo in Early Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy – Final Analysis. San Antonio: Cancer Therapy & Research Center at UT Health Science Center. Hentet fra http://cancerres.aacrjournals.org/content/71/24_Supplement/S2-3

Pathak, N., Sharma, A., Elavarasi, A., Sankar, J., Deo, S. V. S., Sharma, D. N., Mathur, S., Kumar, S., ... Batra, A. (2022). Moment of truth-adding carboplatin to neoadjuvant/adjuvant chemotherapy in triple negative breast cancer improves overall survival: An individual participant data and trial-level Meta-analysis. Breast, 64, 7-18.

Peccatori, F. A., Azim, H. A. ,. J., Orecchia, R., Hoekstra, H. J., Pavlidis, N., Kesic, V., & Pentheroudakis, G. (2013). Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology, 24 Suppl 6, vi160-70.

Peled, A. W., Irwin, C. S., Hwang, E. S., Ewing, C. A., Alvarado, M., & Esserman, L. J. (2014). Total skin-sparing mastectomy in BRCA mutation carriers. Annals of surgical oncology, 21(1), 37-41.

Penault-Llorca, F., Andre, F., Sagan, C., Lacroix-Triki, M., Denoux, Y., Verriele, V., Jacquemier, J., Baranzelli, M. C., ... Roche, H. (2009). Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer. Journal of clinical oncology, 27(17), 2809-2815.

Perez, E. A., Romond, E. H., Suman, V. J., Jeong, J. H., Sledge, G., Geyer, C. E. ,. J., Martino, S., Rastogi, P., ... Wolmark, N. (2014). Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. Journal of clinical oncology, 32(33), 3744-52.

Perez, E. A., Suman, V. J., Davidson, N. E., Gralow, J. R., Kaufman, P. A., Visscher, D. W., Chen, B., Ingle, J. N., ... Jenkins, R. B. (2011). Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. Journal of clinical oncology, 29(34), 4491-4497.

Peters, N. H., van Esser, S., van den Bosch, M. A., Storm, R. K., Plaisier, P. W., van Dalen, T., Diepstraten, S. C., Weits, T., ... Peeters, P. H. (2011). Preoperative MRI and surgical management in patients with nonpalpable breast cancer: the MONET - randomised controlled trial. European journal of cancer, 47(6), 879-86.

Peto, R., Davies, C., Godwin, J., Gray, R., Pan, H. C., Clarke, M., Cutter, D., Darby, S., ... Pritchard, K. (2012). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet, 379(9814), 432-444.

Petrillo, A., Fusco, R., Vallone, P., Filice, S., Granata, V., Petrosino, T., Rosaria Rubulotta, M., Setola, S. V., ... Botti, G. (2020). Digital breast tomosynthesis and contrast-enhanced dual-energy digital mammography alone and in combination compared to 2D digital synthetized mammography and MR imaging in breast cancer detection and classification. The breast journal, 26(5), 860-872.

Petruolo, O. A., Pilewskie, M., Patil, S., Barrio, A. V., Stempel, M., Wen, H. Y., & Morrow, M. (2017). Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy. Annals of surgical oncology, 24(9), 2556-2562.

Phi, X. A., Houssami, N., Obdeijn, I. M., Warner, E., Sardanelli, F., Leach, M. O., Riedl, C. C., Trop, I., ... de Bock, G. H. (2015). Magnetic resonance imaging improves breast screening sensitivity in BRCA mutation carriers age >/= 50 years: evidence from an individual patient data meta-analysis. Journal of clinical oncology, 33(4), 349-56.

Piccart, M. J., de Valeriola, D., Dal Lago, L., de Azambuja, E., Demonty, G., Lebrun, F., Bernard-Marty, C., Colozza, M., & Cufer, T. (2005). Adjuvant chemotherapy in 2005: standards and beyond. Breast, 14(6), 439-445.

Piccart, M., Hortobagyi, G. N., Campone, M., Pritchard, K. I., Lebrun, F., Ito, Y., Noguchi, S., Perez, A., ... Baselga, J. (2014). Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2dagger. Annals of oncology, 25(12), 2357-62.

Piccart, M., van 't Veer, L. J., Poncet, C., Lopes Cardozo, J. M. N., Delaloge, S., Pierga, J. Y., Vuylsteke, P., Brain, E., ... Rutgers, E. J. T. (2021). 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. The Lancet. Oncology, 22(4), 476-488.

Piccart, M., Procter, M., Fumagalli, D., Azambuja, E. d., Clark, E., Ewer, M. S., Restuccia, E., Jerusalem, G., ... Investigators (2021). Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. Journal of clinical oncology, 39(13), 1448-1457.

Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., ... Gelber, R. D. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. New England Journal of Medicine, 353(16), 1659-1672.

Piper, M., Peled, A. W., Sbitany, H., Foster, R. D., Esserman, L. J., & Price, E. R. (2016). Comparison of Mammographic Findings Following Oncoplastic Mammoplasty and Lumpectomy Without Reconstruction. Annals of surgical oncology, 23(1), 65-71.

Pivot, X., Romieu, G., Debled, M., Pierga, J. Y., Kerbrat, P., Bachelot, T., Lortholary, A., Espie, M., ... Kramar, A. (2013). 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. The Lancet. Oncology, 14(8), 741-8.

Poggio, F., Bruzzone, M., Ceppi, M., Ponde, N. F., La Valle, G., Del Mastro, L., de Azambuja, E., & Lambertini, M. (2018). Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Annals of oncology, 29(7), 1497-1508.

Poortmans, P. M., Collette, S., Kirkove, C., Van Limbergen, E., Budach, V., Struikmans, H., Collette, L., Fourquet, A., ... Van den Bogaert, W. (2015). Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer. New England Journal of Medicine, 373(4), 317-27.

Potter, S., Conroy, E. J., Cutress, R. I., Williamson, P. R., Whisker, L., Thrush, S., Skillman, J., Barnes, N. L. P., ... Holcombe, C. (2019). Short-term safety outcomes of mastectomy and immediate implant-based breast reconstruction with and without mesh (iBRA): a multicentre, prospective cohort study. The Lancet. Oncology, 20(2), 254-266.

Prat, A., Saura, C., Pascual, T., Hernando, C., Muñoz, M., Paré, L., González Farré, B., Fernández, P. L., ... Gavilá, J. (2020). Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. The Lancet. Oncology, 21(1), 33-43.

Pronzato, P., Campora, E., Amoroso, D., Bertelli, G., Botto, F., Conte, P. F., Sertoli, M. R., & Rosso, R. (1989). Impact of administration-related factors on outcome of adjuvant chemotherapy for primary breast cancer. American journal of clinical oncology, 12(6), 481-485.

Quiet, C. A., Ferguson, D. J., Weichselbaum, R. R., & Hellman, S. (1995). Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up. Journal of clinical oncology, 13(5), 1144-1151.

Radovanovic, Z., Ranisavljevic, M., Radovanovic, D., Vicko, F., Ivkovic-Kapicl, T., & Solajic, N. (2018). Nipple-Sparing Mastectomy with Primary Implant Reconstruction: Surgical and Oncological Outcome of 435 Breast Cancer Patients. Breast Care (Basel), 13(5), 373-378.

Ragaz, J., Olivotto, I. A., Spinelli, J. J., Phillips, N., Jackson, S. M., Wilson, K. S., Knowling, M. A., Coppin, C. M., ... Manji, M. (2005). Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. Journal of the National Cancer Institute, 97(2), 116-126.

Ragaz, J., Jackson, S. M., Le, N., Plenderleith, I. H., Spinelli, J. J., Basco, V. E., Wilson, K. S., Knowling, M. A., ... Olivotto, I. A. (1997). Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. New England Journal of Medicine, 337(14), 956-962.

Rageth, C. J., O'Flynn, E. A. M., Pinker, K., Kubik-Huch, R. A., Mundinger, A., Decker, T., Tausch, C., Dammann, F., ... Varga, Z. (2019). Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). Breast cancer research and treatment, 174(2), 279-296.

Rakha, E. A., Pinder, S. E., Bartlett, J. M., Ibrahim, M., Starczynski, J., Carder, P. J., Provenzano, E., Hanby, A., ... Ellis, I. O. (2015). Updated UK Recommendations for HER2 assessment in breast cancer. Journal of clinical pathology, 68(2), 93-9.

Rakovitch, E., Nofech-Mozes, S., Narod, S. A., Hanna, W., Thiruchelvam, D., Saskin, R., Taylor, C., Tuck, A., ... Paszat, L. (2013). Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis. Breast cancer research and treatment, 138(2), 581-590.

Ramakrishna, N., Temin, S., Chandarlapaty, S., Crews, J. R., Davidson, N. E., Esteva, F. J., Giordano, S. H., Kirshner, J. J., ... Lin, N. U. (2018). Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. Journal of clinical oncology, 36(27), 2804-2807.

Rastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., Margolese, R. G., Hoehn, J. L., ... Wolmark, N. (2008). Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. Journal of clinical oncology, 26(5), 778-785.

Rastogi, P., O'Shaughnessy, J., Martin, M., Boyle, F., Cortes, J., Rugo, H. S., Goetz, M. P., Hamilton, E. P., ... Johnston, S. (2024). Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes. Journal of clinical oncology, 42(9), 987-993.

Razavi, P., Chang, M. T., Xu, G., Bandlamudi, C., Ross, D. S., Vasan, N., Cai, Y., Bielski, C. M., ... Baselga, J. (2018). The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell, 34(3), 427-438 e6.

Recht, A., Comen, E. A., Fine, R. E., Fleming, G. F., Hardenbergh, P. H., Ho, A. Y., Hudis, C. A., Hwang, E. S., ... Edge, S. B. (2016). Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. Practical radiation oncology, 6(6), e219-e234.

Recht, A., Edge, S. B., Solin, L. J., Robinson, D. S., Estabrook, A., Fine, R. E., Fleming, G. F., Formenti, S., ... Pfister, D. G. (2001). Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. Journal of clinical oncology, 19(5), 1539-1569.

Reed, W., Hannisdal, E., Boehler, P. J., Gundersen, S., Host, H., & Marthin, J. (2000). The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer, 88(4), 804-813.

Regan, M. M., Neven, P., Giobbie-Hurder, A., Goldhirsch, A., Ejlertsen, B., Mauriac, L., Forbes, J. F., Smith, I., ... Thurlimann, B. (2011). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. The Lancet. Oncology, 12(12), 1101-1108.

Reinertsen, K. V., Cvancarova, M., Wist, E., Bjøro, T., Dahl, A. A., Danielsen, T., & Fossa, S. D. (2009). Thyroid function in women after multimodal treatment for breast cancer stage II/III: comparison with controls from a population sample. International journal of radiation oncology, biology, physics, 75(3), 764-770.

Research Council of Norway (2015). Research based evaluation of the Norwegian Breast Cancer Screening Program: final report Oslo: Research Council of Norway. Hentet fra https://www.regjeringen.no/contentassets/444d08daf15e48aca5321f2cefaac511/mammografirapport-til-web.pdf

Rigakos, G., & Razis, E. (2012). BRCAness: finding the Achilles heel in ovarian cancer. Oncologist, 17(7), 956-62.

Rimawi, M., Ferrero, J. M., de la Haba-Rodriguez, J., Poole, C., De Placido, S., Osborne, C. K., Hegg, R., Easton, V., ... Arpino, G. (2018). First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. Journal of clinical oncology, 36(28), 2826-2835.

Robert, N. J., Vogel, C. L., Henderson, I. C., Sparano, J. A., Moore, M. R., Silverman, P., Overmoyer, B. A., Shapiro, C. L., ... Gabizon, A. A. (2004). The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. Seminars in oncology, 31(6 Suppl 13), 106-146.

Robertson, J. F. R., Bondarenko, I. M., Trishkina, E., Dvorkin, M., Panasci, L., Manikhas, A., Shparyk, Y., Cardona-Huerta, S., ... Ellis, M. J. (2016). Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet, 388(10063), 2997-3005.

Robertson, S. A., Rusby, J. E., & Cutress, R. I. (2014). Determinants of optimal mastectomy skin flap thickness. The British journal of surgery, 101(8), 899-911.

Robson, M. E., Tung, N., Conte, P., Im, S. A., Senkus, E., Xu, B., Masuda, N., Delaloge, S., ... Domchek, S. M. (2019). OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of oncology, 30(4), 558-566.

Robson, M., Im, S. A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., ... Conte, P. (2017). Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. New England Journal of Medicine, 377(6), 523-533.

Rojas, M. P., Telaro, E., Russo, A., Moschetti, I., Coe, L., Fossati, R., Palli, D., del Roselli, T. M., & Liberati, A. (2005). Follow-up strategies for women treated for early breast cancer. Cochrane database of systematic reviews, (1), CD001768.

Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E. ,., Davidson, N. E., Tan-Chiu, E., Martino, S., ... Wolmark, N. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England Journal of Medicine, 353(16), 1673-1684.

Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J., Apffelstaedt, J., Hussein, M. A., ... Seaman, J. J. (2003). Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer, 98(8), 1735-1744.

Rosen, P. R., Groshen, S., Saigo, P. E., Kinne, D. W., & Hellman, S. (1989). A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. Journal of clinical oncology, 7(3), 355-66.

Rosen, P. P., Groshen, S., Saigo, P. E., Kinne, D. W., & Hellman, S. (1989). Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. Journal of clinical oncology, 7(9), 1239-51.

Rosen, L. S., Gordon, D., Kaminski, M., Howell, A., Belch, A., Mackey, J., Apffelstaedt, J., Hussein, M., ... Ambros, Y. (2001). Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer journal, 7(5), 377-387.

Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Kooperberg, C., Stefanick, M. L., Jackson, R. D., Beresford, S. A., ... Ockene, J. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA, 288(3), 321-333.

Rubino, C., Arriagada, R., Delaloge, S., & Lê, M. G. (2010). Relation of risk of contralateral breast cancer to the interval since the first primary tumour. British Journal of Cancer, 102(1), 213-9.

Rubio, I. T., Wyld, L., Marotti, L., Athanasiou, A., Regitnig, P., Catanuto, G., Schoones, J. W., Zambon, M., ... Gilbert, F. (2024). European guidelines for the diagnosis, treatment and follow-up of breast lesions with uncertain malignant potential (B3 lesions) developed jointly by EUSOMA, EUSOBI, ESP (BWG) and ESSO. European journal of surgical oncology, 50(1), 107292.

Rudenstam, C. M., Zahrieh, D., Forbes, J. F., Crivellari, D., Holmberg, S. B., Rey, P., Dent, D., Campbell, I., ... Coates, A. S. (2006). Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. Journal of clinical oncology, 24(3), 337-44.

Rugo, H. S., Barry, W. T., Moreno-Aspitia, A., Lyss, A. P., Cirrincione, C., Leung, E., Mayer, E. L., Naughton, M., ... Winer, E. P. (2015). Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). Journal of clinical oncology, 33(21), 2361-9.

Rugo, H. S., Bardia, A., Marmé, F., Cortés, J., Schmid, P., Loirat, D., Trédan, O., Ciruelos, E., ... Tolaney, S. M. (2023). Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet, 402(10411), 1423-1433.

Rugo, H. S., Finn, R. S., Diéras, V., Ettl, J., Lipatov, O., Joy, A. A., Harbeck, N., Castrellon, A., ... Slamon, D. J. (2019). Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast cancer research and treatment, 174(3), 719-729.

Rugo, H. S., Lerebours, F., Ciruelos, E., Drullinsky, P., Borrego, M. R., Neven, P., Park, Y. H., Prat, A., ... Chia, S. K. L. (2020). Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results. Journal of clinical oncology, 38(15_suppl), 1006.

Ruhstaller, T., Giobbie-Hurder, A., Colleoni, M., Jensen, M. B., Ejlertsen, B., de Azambuja, E., Neven, P., Láng, I., ... Regan, M. M. (2019). Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. Journal of clinical oncology, 37(2), 105-114.

Rusby, J. E., Paramanathan, N., Laws, S. A., & Rainsbury, R. M. (2008). Immediate latissimus dorsi miniflap volume replacement for partial mastectomy: use of intra-operative frozen sections to confirm negative margins. American journal of surgery, 196(4), 512-8.

Ryberg, M., Nielsen, D., Cortese, G., Nielsen, G., Skovsgaard, T., & Andersen, P. K. (2008). New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. Journal of the National Cancer Institute, 100(15), 1058-1067.

Sabate, J. M., Clotet, M., Torrubia, S., Gomez, A., Guerrero, R., de las Heras, P., & Lerma, E. (2007). Radiologic evaluation of breast disorders related to pregnancy and lactation. Radiographics, 27 Suppl 1, S101-24.

Safra, T., Muggia, F., Jeffers, S., Tsao-Wei, D. D., Groshen, S., Lyass, O., Henderson, R., Berry, G., & Gabizon, A. (2000). Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Annals of oncology, 11(8), 1029-1033.

Safran, T., Al-Halabi, B., Viezel-Mathieu, A., Boileau, J. F., & Dionisopoulos, T. (2021). Skin-Reducing Mastectomy with Immediate Prepectoral Reconstruction: Surgical, Aesthetic, and Patient-Reported Outcomes with and without Dermal Matrices. Plastic and reconstructive surgery, 147(5), 1046-1057.

Sagen, A., Kåresen, R., & Risberg, M. A. (2009). Influence of physical activity on the development on arm lymphedema after breast cancer surgery. A prospective randomized controlled trial with two years follow-up.. Acta Oncologica, 48(4), 1102-1110.

Sakakibara, M., Nagashima, T., Sangai, T., Nakamura, R., Fujimoto, H., Arai, M., Kazama, T., Hashimoto, H., ... Miyazaki, M. (2008). Breast-conserving surgery using projection and reproduction techniques of surgical-position breast MRI in patients with ductal carcinoma in situ of the breast. Journal of the American College of Surgeons, 207(1), 62-8.

Salibian, A. A., Bekisz, J. M., Kussie, H. C., Thanik, V. D., Levine, J. P., Choi, M., & Karp, N. S. (2021). Do We Need Support in Prepectoral Breast Reconstruction? Comparing Outcomes with and without ADM. Plastic and reconstructive surgery. Global open, 9(8), e3745.

Salibian, A. A., Frey, J. D., Bekisz, J. M., Karp, N. S., & Choi, M. (2019). Ischemic Complications after Nipple-sparing Mastectomy: Predictors of Reconstructive Failure in Implant-based Reconstruction and Implications for Decision-making. Plastic and reconstructive surgery. Global open, 7(5), e2280.

Salibian, A. A., Frey, J. D., Karp, N. S., & Choi, M. (2019). Does Staged Breast Reduction before Nipple-Sparing Mastectomy Decrease Complications? A Matched Cohort Study between Staged and Nonstaged Techniques. Plastic and reconstructive surgery, 144(5), 1023-1032.

Salvadori, B., Rovini, D., Squicciarini, P., Conti, R., Cusumano, F., & Grassi, M. (1992). Surgery for local recurrences following deficient radical mastectomy for breast cancer: a selected series of 39 cases. European journal of surgical oncology, 18(5), 438-441.

Sardanelli, F., Fallenberg, E. M., Clauser, P., Trimboli, R. M., Camps-Herrero, J., Helbich, T. H., & Forrai, G. (2017). Mammography: an update of the EUSOBI recommendations on information for women. Insights Imaging, 8(1), 11-18.

Sardanelli, F., Boetes, C., Borisch, B., Decker, T., Federico, M., Gilbert, F. J., Helbich, T., Heywang-Kobrunner, S. H., ... Wilson, R. (2010). Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. European journal of cancer, 46(8), 1296-316.

Saura, C., Oliveira, M., Feng, Y. H., Dai, M. S., Chen, S. W., Hurvitz, S. A., Kim, S. B., Moy, B., ... Investigators, N. (2020). Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With >/= 2 HER2-Directed Regimens: Phase III NALA Trial. Journal of clinical oncology, 38(27), 3138-3149.

Sawaki, M., Taira, N., Uemura, Y., Saito, T., Baba, S., Kobayashi, K., Kawashima, H., Tsuneizumi, M., ... Mukai, H. (2020). Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients. Journal of clinical oncology, 38(32), 3743-3752.

Scaltriti, M., Rojo, F., Ocana, A., Anido, J., Guzman, M., Cortes, J., Di Cosimo, S., Matias-Guiu, X., ... Baselga, J. (2007). Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. Journal of the National Cancer Institute, 99(8), 628-38.

Schaverien, M. V., Stallard, S., Dodwell, D., & Doughty, J. C. (2013). Use of boost radiotherapy in oncoplastic breast-conserving surgery - a systematic review. European journal of surgical oncology, 39(11), 1179-85.

Schettini, F., Giudici, F., Giuliano, M., Cristofanilli, M., Arpino, G., Del Mastro, L., Puglisi, F., De Placido, S., ... Generali, D. (2020). Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 112(11), 1089-1097.

Schmid, P., Abraham, J., Chan, S., Wheatley, D., Brunt, A. M., Nemsadze, G., Baird, R. D., Park, Y. H., ... Turner, N. C. (2020). Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. Journal of clinical oncology, 38(5), 423-433.

Schmid, P., Rugo, H. S., Adams, S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Henschel, V., ... Emens, L. A. (2020). Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology, 21(1), 44-59.

Schmid, P., Zaiss, M., Harper-Wynne, C., Ferreira, M., Dubey, S., Chan, S., Makris, A., Nemsadze, G., ... Cortés, J. (2019). Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial. JAMA oncology, 5(11), 1556-63.

Schmid, P., Cortes, J., Dent, R., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., ... O'Shaughnessy, J. (2022). Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. New England Journal of Medicine, 386(6), 556-567.

Schmid, P., Cortes, J., Dent, R., McArthur, H., Pusztai, L., Kümmel, S., Denkert, C., Park, Y. H., ... O'Shaughnessy, J. (2024). Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. New England Journal of Medicine, 391(21), 1981-1991.

Schmitz, K. H., Courneya, K. S., Matthews, C., Demark-Wahnefried, W., Galvao, D. A., Pinto, B. M., Irwin, M. L., Wolin, K. Y., ... Schwartz, A. L. (2010). American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Medicine and science in sports and exercise, 42(7), 1409-1426.

Schnitt, S. J., & Collins, L. C. (2005). Columnar Cell Lesions and Flat Epithelial Atypia of the Breast. Seminars in Breast Disease, 8(2), 100-111.

Schnitt, S. J., & Vincent-Salomon, A. (2003). Columnar cell lesions of the breast. Advances in anatomic pathology, 10(3), 113-124.

Schou Bredal, I., Smeby, N. A., Ottesen, S., Warncke, T., & Schlichting, E. (2014). Chronic pain in breast cancer survivors: comparison of psychosocial, surgical, and medical characteristics between survivors with and without pain. Journal of pain and symptom management, 48(5), 852-62.

Schouten van der Velden, A. P., Peeters, P. H., Koot, V. C., & Hennipman, A. (2006). Local recurrences after conservative treatment of ductal carcinoma-in-situ of the breast without radiotherapy: the effect of age. Annals of surgical oncology, 13(7), 990-998.

Schroth, W., Goetz, M. P., Hamann, U., Fasching, P. A., Schmidt, M., Winter, S., Fritz, P., Simon, W., ... Brauch, H. (2009). Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA, 302(13), 1429-1436.

Schuck, A., Konemann, S., Heinen, K., Rube, C. E., Hesselmann, S., Reinartz, G., Schuller, P., Micke, O., ... Willich, N. (2002). Microscopic residual disease is a risk factor in the primary treatment of breast cancer. Strahlentherapie und Onkologie, 178(6), 307-313.

Schwaibold, F., Fowble, B. L., Solin, L. J., Schultz, D. J., & Goodman, R. L. (1991). The results of radiation therapy for isolated local regional recurrence after mastectomy. International journal of radiation oncology, biology, physics, 21(2), 299-310.

Schwartz, G. F., Solin, L. J., Olivotto, I. A., Ernster, V. L., & Pressman, P. I. (2000). Consensus Conference on the Treatment of In Situ Ductal Carcinoma of the Breast, April 22-25, 1999. Cancer, 88(4), 946-954.

Schwartz, J. D. (2019). Toward a More Definitive Goldilocks Mastectomy: Simultaneous Addition of the Lateral Intercostal Perforator Flap. Plastic and reconstructive surgery. Global open, 7(3), e2132.

Sechopoulos, I., Suryanarayanan, S., Vedantham, S., D'Orsi, C. J., & Karellas, A. (2008). Radiation dose to organs and tissues from mammography: Monte Carlo and phantom study. Radiology, 246(2), 434-43.

Seminog, O. O., & Goldacre, M. J. (2015). Age-specific risk of breast cancer in women with neurofibromatosis type 1. British Journal of Cancer, 112(9), 1546-8.

Sessa, C., Balmana, J., Bober, S. L., Cardoso, M. J., Colombo, N., Curigliano, G., Domchek, S. M., Evans, D. G., ... clinicalguidelines@esmo.org, E. G. C. E. a. (2023). Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. Annals of oncology, 34(1), 33-47.

Sestak, I., Dowsett, M., Zabaglo, L., Lopez-Knowles, E., Ferree, S., Cowens, J. W., & Cuzick, J. (2013). Factors predicting late recurrence for estrogen receptor-positive breast cancer. Journal of the National Cancer Institute, 105(19), 1504-11.

Seth, A. K., & Cordeiro, P. G. (2020). Stability of Long-Term Outcomes in Implant-Based Breast Reconstruction: An Evaluation of 12-Year Surgeon- and Patient-Reported Outcomes in 3489 Nonirradiated and Irradiated Implants. Plastic and reconstructive surgery, 146(3), 474-484.

Sewart, E., Turner, N. L., Conroy, E. J., Cutress, R. I., Skillman, J., Whisker, L., Thrush, S., Barnes, N., ... the Breast Reconstruction Research, C. (2021). Patient-reported outcomes of immediate implant-based breast reconstruction with and without biological or synthetic mesh. BJS Open, 5(1)

Sewart, E., Turner, N. L., Conroy, E. J., Cutress, R. I., Skillman, J., Whisker, L., Thrush, S., Barnes, N., ... Potter, S. (2020). The Impact of Radiotherapy on Patient-reported Outcomes of Immediate Implant-based Breast Reconstruction With and Without Mesh. Annals of surgery, Jul 9 [Epub ahead of print]

Shannon, C., Ashley, S., & Smith, I. E. (2003). Does timing of adjuvant chemotherapy for early breast cancer influence survival?. Journal of clinical oncology, 21(20), 3792-3797.

Sharif, S., Moran, A., Huson, S. M., Iddenden, R., Shenton, A., Howard, E., & Evans, D. G. (2007). Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. Journal of medical genetics, 44(8), 481-4.

Sikov, W. M., Berry, D. A., Perou, C. M., Singh, B., Cirrincione, C. T., Tolaney, S. M., Kuzma, C. S., Pluard, T. J., ... Winer, E. P. (2015). Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). Journal of clinical oncology, 33(1), 13-21.

Silver, D. P., Richardson, A. L., Eklund, A. C., Wang, Z. C., Szallasi, Z., Li, Q., Juul, N., Leong, C. O., ... Garber, J. E. (2010). Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. Journal of clinical oncology, 28(7), 1145-53.

Silverstein, M. J., Poller, D. N., Waisman, J. R., Colburn, W. J., Barth, A., Gierson, E. D., Lewinsky, B., Gamagami, P., & Slamon, D. J. (1995). Prognostic classification of breast ductal carcinoma-in-situ. Lancet, 345(8958), 1154-1157.

Simon, J. A., Gaines, T., & LaGuardia, K. D. (2016). Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial. Menopause, 23(11), 1214-1221.

Simpson, P. T., Gale, T., Reis-Filho, J. S., Jones, C., Parry, S., Sloane, J. P., Hanby, A., Pinder, S. E., ... Lakhani, S. R. (2005). Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis. American journal of surgical pathology, 29(6), 734-746.

Sjöstrom, J., Blomqvist, C., Mouridsen, H., Pluzanska, A., Ottosson-Lönn, S., Bengtsson, N. O., Østenstad, B., Mjaaland, I., ... Bergh, J. (1999). Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. European journal of cancer, 35(8), 1194-1201.

Skaane, P. (2022). Contrast-enhanced mammography for screening recalls: a problem-solving assessment tool ready for use?. European radiology, 32(11), 7386-7387.

Skillman, J., McManus, P., Bhaskar, P., Hamilton, S., Roy, P. G., & O'Donoghue, J. M. (2022). UK Guidelines for Lipomodelling of the Breast on behalf of Plastic, Reconstructive and Aesthetic Surgery and Association of Breast Surgery Expert Advisory Group. Journal of plastic, reconstructive & aesthetic surgery : JPRAS, 75, 511-18.

Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235(4785), 177-182.

Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., ... Ullrich, A. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science, 244(4905), 707-712.

Slamon, D., Eiermann, W., Robert, N., Giermek, J., Martin, M., Jasiowka, M., Mackey, J., Chan, A., ... Investigators, O. B. o. t. B. (2016). Abstract S5-04: Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer. Cancer Research, 76(4_Suppl), S5-04.

Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S. A., Petrakova, K., Bianchi, G. V., ... Jerusalem, G. (2018). Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. Journal of clinical oncology, 36(24), 2465-2472.

Slamon, D., Lipatov, O., Nowecki, Z., McAndrew, N., Kukielka-Budny, B., Stroyakovskiy, D., Yardley, D. A., Huang, C. S., ... Hortobagyi, G. (2024). Ribociclib plus Endocrine Therapy in Early Breast Cancer. New England Journal of Medicine, 390(12), 1080-1091.

Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., ... Crown, J. (2011). Adjuvant trastuzumab in HER2-positive breast cancer. New England Journal of Medicine, 365(14), 1273-1283.

Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., ... Norton, L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine, 344(11), 783-792.

Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S. A., Petrakova, K., Bianchi, G. V., ... Jerusalem, G. (2020). Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. New England Journal of Medicine, 382(6), 514-524.

Sledge, G. W. ,. J., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., ... Llombart-Cussac, A. (2017). MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. Journal of clinical oncology, 35(25), 2875-2884.

Sledge, G. W. ,. J., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., ... Llombart-Cussac, A. (2020). The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA oncology, 6(1), 116-124.

Sobti, N., Weitzman, R. E., Nealon, K. P., Jimenez, R. B., Gfrerer, L., Mattos, D., Ehrlichman, R. J., Gadd, M., ... Liao, E. C. (2020). Evaluation of capsular contracture following immediate prepectoral versus subpectoral direct-to-implant breast reconstruction. Scientific reports, 10(1), 1137.

Sonke, G. S., Nijhof, A. V. O. -., Wortelboer, N., Noort, V. v. d., Swinkels, A. C. P., Blommestein, H. M., Beeker, A., Beelen, K., ... Jager, A. (2023). Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). Journal of clinical oncology, 41(17 suppl), LBA1000.

Sorrentino, L., Regolo, L., Scoccia, E., Petrolo, G., Bossi, D., Albasini, S., Caruso, A., Vanna, R., ... Corsi, F. (2019). Autologous fat transfer after breast cancer surgery: An exact-matching study on the long-term oncological safety. European journal of surgical oncology,

Sotiriou, C., Lacroix, M., Lespagnard, L., Larsimont, D., Paesmans, M., & Body, J. J. (2001). Interleukins-6 and -11 expression in primary breast cancer and subsequent development of bone metastases. Cancer letters, 169(1), 87-95.

Southey, M. C., Goldgar, D. E., Winqvist, R., Pylkäs, K., Couch, F., Tischkowitz, M., Foulkes, W. D., Dennis, J., ... Milne, R. L. (2016). PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. Journal of medical genetics, 53(12), 800-811.

Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E. ,. J., Dees, E. C., ... Sledge, G. W. ,. J. (2018). Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. New England Journal of Medicine, 379(2), 111-121.

Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E. ,. J., Dees, E. C., ... Sledge, G. W. (2015). Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. New England Journal of Medicine, 373(21), 2005-14.

Sparano, J. A., Gray, R. J., Ravdin, P. M., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E. ,. J., ... Sledge, G. W. ,. J. (2019). Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. New England Journal of Medicine, 380(25), 2395-2405.

Sparano, J. A., Wang, M., Martino, S., Jones, V., Perez, E. A., Saphner, T., Wolff, A. C., Sledge, G. W. ,. J., ... Davidson, N. E. (2008). Weekly paclitaxel in the adjuvant treatment of breast cancer. New England Journal of Medicine, 358(16), 1663-71.

Spear, S. L., Coles, C. N., Leung, B. K., Gitlin, M., Parekh, M., & Macarios, D. (2016). The Safety, Effectiveness, and Efficiency of Autologous Fat Grafting in Breast Surgery. Plastic and reconstructive surgery. Global open, 4(8), e827.

Speck, R. M., Courneya, K. S., Masse, L. C., Duval, S., & Schmitz, K. H. (2010). An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. Journal of cancer survivorship : research and practice, 4(2), 87-100.

Spring, L. M., Gupta, A., Reynolds, K. L., Gadd, M. A., Ellisen, L. W., Isakoff, S. J., Moy, B., & Bardia, A. (2016). Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis. JAMA oncology, 2(11), 1477-1486.

Spronk, I., Schellevis, F. G., Burgers, J. S., de Bock, G. H., & Korevaar, J. C. (2018). Incidence of isolated local breast cancer recurrence and contralateral breast cancer: A systematic review. Breast, 39, 70-79.

Staaf, J., Glodzik, D., Bosch, A., Vallon-Christersson, J., Reutersward, C., Hakkinen, J., Degasperi, A., Amarante, T. D., ... Nik-Zainal, S. (2019). Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study. Nature medicine, 25(10), 1526-153.

Stark, B., Magneli, M., van Heijningen, I., Parreira, C., Bosch, U., Rouif, M., & Halle, M. (2021). Considerations on the Demography of BIA-ALCL in European Countries Based on an E(A)SAPS Survey. Aesthetic plastic surgery, 45(6), 2639-2644.

Steenbruggen, T. G., van Werkhoven, E., van Ramshorst, M. S., Dezentjé, V. O., Kok, M., Linn, S. C., Siesling, S., & Sonke, G. S. (2020). Adjuvant chemotherapy in small node-negative triple-negative breast cancer. European journal of cancer, 135, 66-74.

Stensheim, H., Cvancarova, M., Møller, B., & Fosså, S. D. (2011). Pregnancy after adolescent and adult cancer: A population-based matched cohort study. International Journal of Cancer, 129(5), 1225-1236.

Stokes, E. L., Tyldesley, S., Woods, R., Wai, E., & Olivotto, I. A. (2011). Effect of nodal irradiation and fraction size on cardiac and cerebrovascular mortality in women with breast cancer treated with local and locoregional radiotherapy. International journal of radiation oncology, biology, physics, 80(2), 403-409.

Stopeck, A. T., Lipton, A., Body, J. J., Steger, G. G., Tonkin, K., de Boer, R. H., Lichinitser, M., Fujiwara, Y., ... Braun, A. (2010). Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. Journal of clinical oncology, 28(35), 5132-5139.

Strnad, V., Ott, O. J., Hildebrandt, G., Kauer-Dorner, D., Knauerhase, H., Major, T., Lyczek, J., Guinot, J. L., ... Polgar, C. (2016). 5-year results of accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy versus whole-breast irradiation with boost after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: a randomised, phase 3, non-inferiority trial. Lancet, 387(10015), 229-38.

Stuart, K. E., Houssami, N., Taylor, R., Hayen, A., & Boyages, J. (2015). Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis. BMC Cancer, 15, 890.

Swain, S. M., Kim, S. B., Cortes, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J. M., ... Baselga, J. (2013). Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. The Lancet. Oncology, 14(6), 461-471.

Swain, S. M., Baselga, J., Kim, S. B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J. M., ... Cortes, J. (2015). Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. New England Journal of Medicine, 372(8), 724-34.

Swain, S. M., Jeong, J. H., Geyer, C. E. ,. J., Costantino, J. P., Pajon, E. R., Fehrenbacher, L., Atkins, J. N., Polikoff, J., ... Wolmark, N. (2010). Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. New England Journal of Medicine, 362(22), 2053-65.

Tabar, L., Vitak, B., Chen, H. H., Yen, M. F., Duffy, S. W., & Smith, R. A. (2001). Beyond randomized controlled trials: organized mammographic screening substantially reduces breast carcinoma mortality. Cancer, 91(9), 1724-1731.

Takeda, A., Shigematsu, N., Kondo, M., Amemiya, A., Kawaguchi, O., Sato, M., Kutsuki, S., Toya, K., ... Kubo, A. (2000). The modified tangential irradiation technique for breast cancer: how to cover the entire axillary region. International journal of radiation oncology, biology, physics, 46(4), 815-822.

Tamura, K., Imamura, C. K., Takano, T., Saji, S., Yamanaka, T., Yonemori, K., Takahashi, M., Tsurutani, J., ... Tanigawara, Y. (2020). CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study. Journal of clinical oncology, 38(6), 558-566.

Tan, A. R., Im, S. A., Mattar, A., Colomer, R., Stroyakovskii, D., Nowecki, Z., De Laurentiis, M., Pierga, J. Y., ... Jackisch, C. (2021). Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. The Lancet. Oncology, 22(1), 85-97.

Tan, P. H., Thike, A. A., Tan, W. J., Thu, M. M., Busmanis, I., Li, H., Chay, W. Y., & Tan, M. H. (2012). Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins. Journal of clinical pathology, 65(1), 69-76.

Tanbo, T., Greggains, G., Storeng, R., Busund, B., Langebrekke, A., & Fedorcsak, P. (2015). Autotransplantation of cryopreserved ovarian tissue after treatment for malignant disease – the first Norwegian results. Acta Obstetricia et Gynecologica Scandinavica, 94(9), 937-941.

Tang, R., Coopey, S. B., Colwell, A. S., Specht, M. C., Gadd, M. A., Kansal, K., McEvoy, M. P., Merrill, A. L., ... Smith, B. L. (2015). Nipple-Sparing Mastectomy in Irradiated Breasts: Selecting Patients to Minimize Complications. Annals of surgical oncology, 22(10), 3331-7.

Tarantino, P., Leone, J., Vallejo, C. T., Freedman, R. A., Waks, A. G., Martínez-Sáez, O., Garrido-Castro, A., Lynce, F., ... Leone, J. P. (2024). Prognosis and treatment outcomes for patients with stage IA triple-negative breast cancer. NPJ breast cancer, 10(1), 26.

Taylor, C., McGale, P., Bronnum, D., Correa, C., Cutter, D., Duane, F. K., Gigante, B., Jensen, M. B., ... Ewertz, M. (2018). Cardiac Structure Injury After Radiotherapy for Breast Cancer: Cross-Sectional Study With Individual Patient Data. Journal of clinical oncology, 36(22), 2288-2296.

Taylor, C., Correa, C., Duane, F. K., Aznar, M. C., Anderson, S. J., Bergh, J., Dodwell, D., Ewertz, M., ... McGale, P. (2017). Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. Journal of clinical oncology, 35(15), 1641-1649.

Taylor, C. W., Brønnum, D., Darby, S. C., Gagliardi, G., Hall, P., Jensen, M. B., McGale, P., Nisbet, A., & Ewertz, M. (2011). Cardiac dose estimates from Danish and Swedish breast cancer radiotherapy during 1977-2001. Radiotherapy and Oncology, 100(2), 176-83.

Telli, M. L., Timms, K. M., Reid, J., Hennessy, B., Mills, G. B., Jensen, K. C., Szallasi, Z., Barry, W. T., ... Richardson, A. L. (2016). Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clinical cancer research, 22(15), 3764-73.

Thamm, O. C., & Andree, C. (2018). Immediate Versus Delayed Breast Reconstruction: Evolving Concepts and Evidence Base. Clinics in plastic surgery, 45(1), 119-127.

Theriault, R. L., & Litton, J. K. (2013). Pregnancy during or after breast cancer diagnosis: what do we know and what do we need to know?. Journal of clinical oncology, 31(20), 2521-2.

Theriault, R. L., Lipton, A., Hortobagyi, G. N., Leff, R., Gluck, S., Stewart, J. F., Costello, S., Kennedy, I., ... Reitsma, D. J. (1999). Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. Journal of clinical oncology, 17(3), 846-854.

Thor, A. D., Berry, D. A., Budman, D. R., Muss, H. B., Kute, T., Henderson, I. C., Barcos, M., Cirrincione, C., ... Liu, E. T. (1998). erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. Journal of the National Cancer Institute, 90(18), 1346-1360.

Thorarinsson, A., Frojd, V., Kolby, L., Ljungdal, J., Taft, C., & Mark, H. (2017). Long-Term Health-Related Quality of Life after Breast Reconstruction: Comparing 4 Different Methods of Reconstruction. Plastic and reconstructive surgery. Global open, 5(6), e1316.

Thorsen, L. B., Offersen, B. V., Danø, H., Berg, M., Jensen, I., Pedersen, A. N., Zimmermann, S. J., Brodersen, H. J., ... Overgaard, J. (2016). DBCG-IMN: A Population-Based Cohort Study on the Effect of Internal Mammary Node Irradiation in Early Node-Positive Breast Cancer. Journal of clinical oncology, 34(4), 314-20.

Thorsen, L. B. J., Overgaard, J., Matthiessen, L. W., Berg, M., Stenbygaard, L., Pedersen, A. N., Nielsen, M. H., Overgaard, M., & Offersen, B. V. (2022). Internal Mammary Node Irradiation in Patients With Node-Positive Early Breast Cancer: Fifteen-Year Results From the Danish Breast Cancer Group Internal Mammary Node Study. Journal of clinical oncology, , Epub ahead of print.

Timbrell, S., Al-Himdani, S., Shaw, O., Tan, K., Morris, J., & Bundred, N. (2017). Comparison of Local Recurrence After Simple and Skin-Sparing Mastectomy Performed in Patients with Ductal Carcinoma In Situ. Annals of surgical oncology, 24(4), 1071-1076.

Tischkowitz, M., Colas, C., Pouwels, S., Hoogerbrugge, N., Group, P. G. D., & European Reference Network, G. (2020). Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome. European journal of human genetics : EJHG, 28(10), 1387-1393.

Tischkowitz, M., Balmana, J., Foulkes, W. D., James, P., Ngeow, J., Schmutzler, R., Voian, N., Wick, M. J., ... Guidelines, C. (2021). Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genetics in medicine, 23(8), 1416-1423.